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ABSTRACT 
Antidepressant medications are an effective treatment option for individuals 
with depression. However, significantly sub-optimal adherence has been observed in 
up to 44% of primary care patients. Almost 40% of patients who discontinue their 
medication experience a return of symptoms. Adherence interventions are therefore 
important, but often require delivery by highly trained clinicians (e.g. physicians). In 
Australia adherence interventions need to have the capacity to be delivered by a 
variety of professionals as a diverse range of clinicians (e.g. allied health) provide 
services to primary care patients under a number of government funded initiatives. 
However, many clinicians lack the requisite knowledge, skills, and beliefs to 
facilitate adherence. Addressing this need is important given that clinicians' beliefs 
may influence the type of treatment that patients receive, such as whether support is 
provided to the patient to use their medication more effectively. Researchers in 
Australia and the UK report successful attempts to increase clinicians' skills, 
knowledge, and beliefs to facilitate adherence to antipsychotic medication. 
Furthermore, when trained clinicians work to facilitate adherence among patients with 
psychosis, significant increases in adherence and reductions in psychopathology are 
obtained, compared with treatment as usual. There are few studies that focus on 
improving medication adherence skills in clinicians working with depressive 
disorders. 
Study 1 surveyed 72 allied health clinicians working in primary care with 
individuals with depression. This study sought to identify clinicians' beliefs about (a) 
medications in general, (b) adequacy to facilitate adherence, (c) their role in 
facilitating adherence, as well as (d) previous training in adherence strategies, and (e) 
self-reported use of use specific adherence strategies. It was hypothesised that more 
positive beliefs and previous training would be related to higher reported use of 
specific adherence strategies. The degree to which these variables predict self-
reported use of adherence strategies was also explored. Results showed clinicians' 
beliefs about adequacy and their role in facilitating adherence predicts self-reported 
use of adherence strategies. Previously trained clinicians reported significantly more 
positive beliefs about adequacy and their role in facilitating adherence. 
Study 2 evaluated the impact of a modified version of the Medication Alliance 
training program on the knowledge, beliefs and skills of 24 allied health clinicians 
working in primary care. It was hypothesised that pre- and post-training measures 
would demonstrate increases in clinicians' knowledge, skill, and beliefs related to 
enhancing adherence amongst individuals with depression. Results showed significant 
increases in knowledge and beliefs to facilitate adherence following training. No 
significant increase in skill was found. These results suggest that Medication Alliance 
techniques can be successfully delivered to improve the knowledge and beliefs of 
allied health cUnicians working in primary care. The next step is to examine the 
impact that clinician training has on patient adherence to antidepressant medication. 
DEPRESSION: A GLOBAL HEALTH CRISIS 
Depression is a major health issue, affecting approximately 5% of the 
Australian population at any one time (Australian Bureau of Statistics [ABS], 2001). 
In 2001 approximately 800 thousand people living in Australia reported experiencing 
problems with mood, including depressive disorders (ABS). Worldwide, depressive 
disorders affect approximately 121 million people (World Health Organisation 
[WHO], n.d.). Depressive disorders are the leading cause of disability, and the fourth 
leading contributor to the global burden of disease (Murray & Lopez, 1996). In 2002, 
depressive disorders were the leading cause of burden of disease for females, and the 
fourth leading cause for males (WHO, 2003). By the year 2020, depressive disorders 
are expected to be the second overall leading contributor to global burden of diseases 
for both men and women (Murray & Lopez). 
Depressive disorders are defined in the Diagnostic and Statistical Manual of 
Mental Disorders, edition text revision (DSM IV-TR, American Psychiatric 
Association [APA], 2000a), as a disturbance in mood, including depressed mood or 
loss of interest or pleasure. They include Major Depressive Disorder (MDD), 
Dysthymic Disorder (DD), and Depressive Disorder Not Otherwise Specified. In 
MDD, a person may experience one or more Major Depressive Episodes, which are 
characterised by at least "2 weeks of depressed mood or loss of interest accompanied 
by at least four additional symptoms of depression" (APA, p. 345). DD is the 
experience of "2 years or more of depressed mood for more days than not, 
accompanied by additional depressive symptoms that do not meet criteria for a Major 
Depressive Episode" (APA, pp. 345). Depressive Disorder Not Otherwise Specified is 
the diagnosis given when depressed mood is a focus of clinical attention but 
symptoms do not meet criteria for another Mood Disorder (APA). 
Prevalence 
Research in primary care settings has found that point prevalence rates for 
depressive disorders are almost double that of the prevalence in community samples, 
suggesting that depressive disorders are common and under-treated in primary care 
settings (Al-Windi, 2005; Steiner et al., 1999). In community samples, point 
prevalence for MDD is reported between 2% to 9% (APA, 2000a; Blazer, Kessler, 
McGonagle, & Swartz, 1994), while in primary care, point prevalence is reported 
between 5% and 20% (Al-Windi; Aragonés et al., 2004; Berardi et al., 2002; 
Christensen, Bundgaard, & Bech, 2001; Katon & Schulberg, 1992; Means-
Christensen, Amau, Tonidandel, Bramson, & Meagher, 2005; Wittchen & Pittrow, 
2002). 
Twelve-month prevalence rates among community samples are comparable 
with that of primary care and are reported between 2.6% to 12.9% in community 
samples (Angst, 1992; Hasin, Goodwin, Stinson, & Grant, 2005; Kessler et al., 1994, 
2003) and 8.3% in primary care samples (Wittchen & Pittrow, 2002). Lower 
prevalence rates have been reported for DD in comparison to MDD. The DSM IV-TR 
reports a point prevalence rate for DD at 3% among the general population (APA, 
2000a), primary care studies reporting slightly higher rate of 4.8% (Aragonés et al., 
2004) and 5.1% (Steiner et al., 1999). 
Course 
Left untreated, the course of depressive disorders can be chronic or patients 
may cycle between relapse and remission. Katon et al. (1995) report that 
approximately 70% of patients in primary care experienced at least two or more prior 
depressive episodes. Up to 25% of people suffering from a depressive disorder 
experience a chronic course (Angst, 1997). After experiencing a single episode of 
depression, the risk of relapse is reported to be as high as 87% within 15 years (Keller 
& Boland, 1998). 
DD has a chronic course, with at least a 2-year period of depressive symptoms 
without relief from these for more than 2 months (APA, 2000a). MDD can also have a 
persistent and chronic course. The DSMIV-TR states that up to 60% of people 
suffering from a single episode of Major Depression will experience a second (APA). 
This percentage increases with each episode, such that after the second episode 70% 
will experience a third, and after the third episode approximately 90% will experience 
a fourth (APA). The risk of recurrence in MDD (i.e., the occurrence of new Major 
Depressive Episode after a 6 month or longer period where depressive symptoms no 
longer meet criteria for MDD; Frank et al., 1991) is reported at around 40% 
(Piccinelli & Wilkinson, 1994; Ramana et al., 1995). 
In a study of primary care patients, Lin et al. (1998) found 37.1% of patients 
experience a return of symptoms within one year or met criteria for MDD at a 19-
month follow-up assessment. Shea et al. (1992) found that patients with a diagnosis of 
MDD experienced recurrence at a rate of between 33% and 50% over an 18-month 
follow-up period, dependent on treatment received. In a 3.5-year follow-up of patients 
with depressive disorders, it was found that 39.3% of the sample experienced the 
recurrence of a Major Depressive Episode (Hoencamp, Haffmans, Griens, 
Huijbrechts, & Heycop ten Ham, 2001). The risk of recurrence is said to increase over 
time, such that after 10 years the rate of recurrence is 75% (Keller & Boland, 1998; 
Piccinelli & Wilkinson, 1994), and up to as high as 87% after 15 years (Keller & 
Boland). 
A chronic course of MDD (the continuous experience of a Major Depressive 
Episode for at least 2 years, with symptom free periods of no longer than 2 months) is 
said to be experienced by between 10% to 25% of individuals (Angst, 1997; Piccinelli 
& Wilkinson, 1994). In a 10-year follow-up of data from the WHO, 10% of people 
experienced a Major Depressive Episode for at least 2 years (Thomicroft & Sartorius, 
1993). Keller et al., (1992) found 12% of their sample had experienced a Major 
Depressive Episode over a 5-year period, while Hoencamp et al., (2001) found 36% 
of their sample had a chronic course. 
Impact of Depressive Disorders 
Individuals with depressive disorders have an increased risk of suicidal 
thoughts and behaviours (Nierenberg et al., 2001). The risk of death by suicide for 
individuals with MDD has been reported at 15% (APA, 2000a; Nierenberg et al.). The 
WHO estimates approximately 850 thousand suicides each year are related to MDD 
(WHO, n.d.). In a study of suicidal ideation among outpatients in the United States, 
researchers found the 50% of individuals with treatment-resistant depression (i.e. 
individuals with a depressive disorder that has previously not responded to 
antidepressant medication) reported suicidal thoughts, while one third reported 
significant suicidal thoughts or suicidal behaviours (Papakostas et al., 2003). The 
contribution of depression to suicidal behaviour has also been assessed in Australia 
(Goldney, 2003). Goldney reported studies of community samples that found 39% to 
47% reported suicidal ideation, and 40% of suicide attempts can be accounted for by 
depressive disorders. 
Not surprisingly, depressive disorders have a significant impact on functioning 
and quality of life. Sufferers often experience significantly greater difficulty working 
and carrying out day to day duties, impairment in physical and social functioning, 
general health concerns, and utilise a greater amount of health services compared with 
individuals who do not meet criteria for a depressive disorder (Goldney, Fisher, 
Wilson, & Cheok, 2000; Hawthorne, Cheok, Goldney, & Fisher, 2003) or individuals 
with a chronic medical condition (Spitzer et al., 1995). Berardi et al. (2002) found that 
depression is associated with severe physical illness, disability, and higher rates of 
medical consultation among primary care patients. In Australia it is estimated that 
disability due to depressive disorders costs the health sector and individual patients in 
excess of one billion dollars (Hawthorne et al.). Given the significant impact 
depressive disorders have on health globally, and the economic burden they carry, the 
enhancement of treatment outcomes is of significant importance. 
TREATING DEPRESSIVE DISORDERS 
Both the United States and Australian guidelines for the treatment of 
depression indicate that antidepressant medication should be considered as a first-line 
treatment for depressive disorders, especially in severe, chronic, and relapsing 
disorders (APA, 2000b; Ellis & Smith, 2002). In addition, psychological therapies 
such as Cognitive Behavioural Therapy and Interpersonal Therapy are suggested as 
alternative first-line treatments in the instance of mild to moderate depression or 
adjunct interventions in severe depression. Reviews of the literature support the use of 
both antidepressant medication and psychological therapies. This combination has 
been reported as superior to either treatment used m isolation for effectively reducing 
severe depressive symptoms, keeping patients in treatment longer, and thus reducing 
the risk of relapse (APA; Friedman et al., 2004; Pampallona, Bollini, Tibaldi, 
Kupelnick, & Munizza, 2004; Thase et al., 1997). Relapse in this context has been 
defined as the return of symptoms that meet criteria for a Major Depressive Episode 
within 6 months of an initial response to antidepressant medication (Frank et al., 
1991), 
However, many patients with depressive disorders are treated in primary care 
settings where resources to provide such psychological interventions are limited 
(Ludman et al., 2003). In fact, the majority of individuals with depressive disorders 
seek treatment from their GP (ABS, 2001; Lin et al., 1998). The efficacy of 
psychological therapies relies heavily on the skills of the clinician delivering the 
therapy, and it has been suggested that psychological therapies should only be 
considered when an appropriately skilled clinician is available (Ellis & Smith, 2002). 
Pharmacotherapy for Depression 
There are many types of antidepressant medications available for the treatment 
of depressive disorders. Treatment guidelines state that the efficacy across different 
types of antidepressant medication is mostly equal, and recommends that medications 
be chosen on the basis of side effects, tolerability, patient preference, and cost (APA, 
2000b; Ellis & Smith, 2002). Antidepressant medications reconmiended for the 
treatment of Depressive Disorders include selective serotonin reuptake inhibitors 
(SSRIs; e.g. fluoxetine, sertraline, paroxetine), serotonin-noradrenalin reuptake 
inhibitors (SNRIs; e.g. venlafaxine, nefazodone), tricyclic antidepressants (TCAs; e.g. 
imipramine, nortriptyline, amitryptiline), and reversible monoamine oxidase inhibitors 
(MAOIs; e.g. moclobemide). 
Premature discontinuation of antidepressant medication can result in relapse in 
up to 50% of patients (Angst, 1997; Hirshfield, 2001). Therefore, recommendations 
have been made regarding the amount of time required to adequately treat symptoms 
and reduce the risk of relapse. In reviews of clinical studies, the average length of 
time considered appropriate for medication treatment to continue is 4 to 6 months 
following remission (Angst; Keller & Boland, 1998). Remission has been defined as a 
period, usually less than 6 months, during which an improvement in symptoms is 
observed (Frank et al., 1991). Ellis and Smith (2002) state that medication should 
continue for at least one year following an initial episode of depression, and that 
treatment be extended to 2 years or more if there is a history of multiple episodes. 
These guidelines have been supported by clinical trials which show antidepressant 
medications effectively treat depression, with significant reductions observed in both 
depressive symptoms and the risk of relapse when antidepressant medication is 
maintained for at least 12 months (Keller et al, 1998; Kocsis et al., 1996). But despite 
these guidelines, non-adherence to antidepressant medication remains a major barrier 
to effective treatment of depressive disorders (Demyttenaere, 2001). 
NON-ADHERENCE TO ANTIDEPRESSANT MEDICATION 
The term 'adherence' is a relatively new term for describing medication-taking 
behaviour. Traditionally, medication-taking behaviour has been described by the term 
'compliance'. Compliance is defined as the extent to which a patient conforms to the 
prescription of a physician, though the use of this term has been criticised as it 
suggests that the patient is wrong and disobedient for not taking their medication as 
prescribed (Aslani & du Pasquier, 2002). The term adherence is thought to overcome 
this by implying greater patient involvement, empowerment, and choice in the 
prescription process (Aslani & du Pasquier). Adherence and compliance are often 
used interchangeably in the literature. The two terms are typically defined as 'the 
degree to which a person adheres to the prescribed treatment regimen" (Maidment, 
Livingston, & Katon, 2002, p. 752). Aslani and du Pasquier suggest that the definition 
of non-adherence broadly means that a patient takes less than the prescribed dose by 
missing or skipping doses. However, broader definitions can include taking too much 
medication or taking medications in the wrong manner (e.g., saving up medications 
and taking them all in the evening even though they were prescribed as three separate 
doses through the day). 
Rates of non-adherence among patients taking antidepressant medication is 
high and variable. In a review by Cramer and Rosenheck (1998), estúnates of non-
adherence rates among patients taking antidepressant medication averaged 35%, 
ranging from 10% to 60% non-adherence. It is reported that approximately 25% of 
primary care patients do not take all of their doses of antidepressant medication over a 
2-week period (Aikens, Nease, Nau, Klinkman, & Schwenk, 2005). Within the first 
month of treatment, between 28% and 35% of primary care patients stopped taking 
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antidepressant medication (Lin et al., 1995; Simon, Von Korff, Wagner, & Barlow, 
1993). It was also found that 29% of patients did not fill their initial prescription 
(Simon et al.). After 3 months, 44% of patients were no longer taking their medication 
(Lin et al.). 
In another primary care study, 60% of patients were found to have stopped 
taking antidepressant medication before completing the recommended 6 months of 
treatment (Katon, Von Korff, Lin, Bush, & Ormel, 1992). Maidment et al. (2002) 
found that approximately 19.4% of 67 older adults in primary care who had been 
prescribed antidepressant medication were variable in the amount to which they 
adhered to their medication, and a further 13.4% reported they never adhered to their 
antidepressant medication. 
The consequences of premature discontinuation of antidepressant medication 
are generally negative. For example, Melfi et al. (1998) found a 77% increase in the 
risk of recurrence of depression amongst patients who had prematurely discontinued 
antidepressant medication, with one quarter of patients experiencing recurrence within 
a 2-year period. Hirschfeld (2001) found that depression recurred in approximately 
60% of cases within 12 months of an episode when antidepressant medication was not 
provided. Of those treated with medication, 33% to 50% of patients relapsed after not 
continuing to taking medication for a recommended period of 6 to 12 months. The 
risk of relapse dropped to between 10% and 15% for patients who continued 
antidepressant medication for the recommended period (Hirschfeld). 
Failure to adhere to medication regimes has been associated not only with 
increased psychopathology, but also increased negative psychosocial consequences 
such as decreased work productivity and reduced quality of life (Keller & Boland, 
1998). 
Factors Influencing Medication Adherence 
Reasons for non-adherence are multifactorial. However, a number of studies 
have identified similar factors influencing adherence to antidepressant medication. In 
particular, a review of the barriers to antidepressant medication adherence identified 
four categories of influence: patient barriers, clinician barriers, clinical and policy 
barriers, and minority population barriers (Unuetzer, Katon, Sullivan, & Miranda, 
1999). Table 1 outlines the key factors influencing adherence to antidepressant 
medication identified in the literature, listed as per the categories suggested by 
Unuetzer et al. 
Theoretical Models to Explain Adherence 
Dunbar-Jacob (1993) notes in psychological research there are many models 
of health behaviour that have been used in an attempt to understand adherence. Three 
of the most widely used models are the Health Belief Model (Becker, 1974; Janz & 
Becker, 1984; Janz, Champion, & Strecher, 2002; Rosenstock, 1974), the Theory of 
Reasoned Action (Ajzen & Fishbein, 1980; Fishbein, 1967) / Theory of Planned 
Behaviour (Ajzen, 1991), and the Common-Sense Model of Self-Regulation 
(Leventhal, Brissette, & Leventhal, 2003; Leventhal, Leventhal, & Contrada, 1998). 
The common element shared by these models is that they regard beliefs as playing a 
major role in predicting health behaviour (Dunbar-Jacob). DiMatteo (1991) noted that 
these theories do not completely explain health behaviour, but that they are useful as 
models for understanding and predicting behaviour. These models are thought to be 
highly comparable in their ability to facilitate understanding and prediction of health 
Table 1 
Barriers to Adherence to Antidepressant Medication 
Barrier Examples 
Patient 
Clinician 
Being poor or older^; lack of knowledge about treatment̂ "*̂ ; 
sensitivity to stigma^; fears of addiction^"^; being male^; 
medical co morbidity^; concurrent medications^; cognitive 
impairment (e.g., remembering to take medication)^; mobility 
(e.g., obtaining prescriptions)^; symptoms of depression (e.g. 
poor motivation)^; side effects'''̂ '®"®; feeling better'''®; adverse 
life events^; cost of medication^'^; denial of illness'; beliefs 
about medication (e.g. need for and harmfulnessy 
Lack of awareness of illness^; lack of skills '̂̂ ; lack of time to 
spend with patients^; not following treatment guidelines''; 
clinician-patient relationship'''̂ '®'̂ '; beliefs about non-adherent 
patients (e.g. difficult, irresponsible)'''® 
Clinical and policy Geographic distance from health care^; concerns about 
privacy^; confidentiality among rural communities^; limited 
resources (e.g., funding for services)^ 
Minority populations Low income^; being of an ethnic background^; cultural beliefs'̂  
® Unuetzer et al., 1999; Demyttenaere, 2001; Maidment et al., 2002; ^ Priest, Vize, Roberts, Roberts, 
& Tylee, 1996;' Lin et al., 1995; ^ Masand, 2000; ® Demyttenaere, 1997; ^ Delgado, 2000;' Bollini, 
Tibaldi, Testa, & Munizza, 2004; ^Aikens et al., 2005. 
behaviour (Brannon & Feist, 2000; Weinstein, 1993), the Common-Sense Model 
of Self-Regulation adding the benefit of considering beliefs related to medication use 
which contribute to patient attitudes towards taking medication (Home, 2003). 
Health Belief Model 
The Health Belief Model (HBM) is one of the most well known psychological 
models of health behaviour and it has been used in the study of adherence behaviour. 
The model emphasizes the importance of attitudes and beliefs in decision-making. 
The HBM proposes that engagement in behaviour (e.g. medication adherence) is 
determined by weighing up the costs and the benefits of carrying out the behaviour 
(Brannon & Feist, 2000; DiMatteo, 1991; Janz et al., 2002). 
This cost-benefit analysis involves weighing four components (or 
perceptions): perceived benefits, perceived susceptibility, perceived severity, and 
perceived barriers (see Figure 1). According to the HBM, these four perceptions 
influence whether an individual will engage in a particular behaviour. In an 
application of the HBM to adherence behaviour Hughes, Hill, and Budd (1997) state 
that an individual will comply with their prescribed medication regime based on the 
perceptions regarding the four components of the model. For example, perceived 
benefits relate to the benefits of treatment as perceived by the individual, or whether 
the individual believes that medication will relieve them of symptoms. Perceived 
susceptibility relates to how likely the individual believes they will continue to 
experience symptoms without taking medication. Perceived severity refers to how 
severe the individual perceives the illness is and/or will be if they do not take 
medication. Perceived barriers refer to the negative consequences of taking 
medication, such as side effects. 
The HBM model has been used to understand and predict medication 
adherence behaviour across a range of health conditions including depression (Adams 
& Scott, 2000; Maidment et al., 2002), psychosis (Adams & Scott; Budd, 
Individual perceptions Likelihood of behaviour 
change 
Figure 1. Health Belief Model (adapted from Janz et al, 2002, p. 52). 
Hughes, & Smith, 1996; Hughes et al., 1997), and HIV/AIDS (Malcolm, Ng, Rosen, 
& Stone, 2003). Research data among patients with depressive disorders appears to 
support the HBM model in that medication adherence is more likely among patients 
whose perceived need for medication outweighs perceived harmfulness of medication 
(Aikens et al., 2005). The model is useful for informing intervention programs that 
aim to change health behaviour by providing an understanding of the patient's 
decision making process which allows the intervention to be tailored to the identified 
perceptions or HBM beliefs (DiMatteo, 1991; Janz et al., 2002). 
Theory of Reasoned Action/Theory of Planned Behaviour 
The Theory of Reasoned Action (TRA) and the Theory of Planned Behaviour 
(TPB) provide a framework for identifying the reasons that determine one's 
motivation or intention to perform a particular behaviour. According to the TRA, 
behaviour is based on intentions to either engage or refrain from that behaviour 
(Brannon & Feist, 2000; DiMatteo, 1991; Montano & Kasprzyk, 2002). The TRA was 
later expanded to include the influence that perceived behavioural control has on 
engaging in behaviour and was renamed the Theory of Planned Behaviour (TPB, 
Ajzen, 1991). The components of the TPB are outlined in Figure 2. 
Intentions are based on an individual's personal attitudes towards the 
behaviour, the individual's perceptions of social pressure to engage or not engage in 
the behaviour {subjective norm), and a person's perceived ability to carry out the 
behaviour in spite of external or environmental barriers (perceived behavioural 
control) (Montano & Kasprzyk). 
Personal attitudes toward behaviour are based on the perceived outcomes or 
consequences of the behaviour (behaviour beliefs), and the evaluation of whether the 
outcomes are positive or negative. For example, if an individual believes that taking 
medication will reduce their symptoms, and that a reduction in symptoms is a positive 
outcome, then they will have a positive attitude toward taking medication. Subjective 
norms are based on an individual's beliefs about whether their peer group or society 
approve or disapprove of the behaviour (normative beliefs) and how much the 
individual wishes to comply with these norms. For example, if an individual believes 
that their peers will approve of them taking medication and the individual is 
motivated to meet the expectations of their peers, then they will hold a subjective 
norm that is likely to facilitate medication taking behaviour. 
Perceived behavioural control is based on the individual's beliefs about 
whether or not there are barriers to performing the behaviour {control beliefs) and the 
extent to which the barriers will hinder the behaviour (actual behavioural control). 
For example, if £in individual believes that medication is too expensive based on their 
income, they are likely to have low perceived behavioural control. Taking all aspects 
of the model together, if an individual holds a positive attitude towards medication, 
has subjective norm beliefs that encourage medication taking, and believe tiiat they 
have the ability to take medication without difficulty, then the individual is likely to 
have high behavioural intention to take medication, which in turn will lead to the 
individual taking the medication. 
Actual 
behavioural 
control 
Figure 2. Theory of Planned Behaviour (Ajzen & Fishbein, 2005). 
This model enables identification of beliefs that affect behaviour. 
Interventions designed to target individual beliefs about health behaviour can lead to 
positive behaviour change (Montano & Kasprzyk, 2002). The model has been used to 
predict adherence behaviour in areas such as medication treatment for bipolar 
disorders (Cochran & Gitlin, 1988), condom use (Albarracin, Johnson, Fishbein, & 
Muellerleile, 2001), and sunscreen use (Martin, Jacobsen, Lucas, Branch, & Ferron, 
1999), highlighting its utility in adherence intervention development. 
Common-Sense Model of Self-Regulation 
As with the HBM and the TRA/TPB, The Common-Sense Model of Self-
Regulation (CSM) looks at patients' attitudes about their illness and how they 
influence intention and behaviour. In addition, the CSM also considers patient beliefs 
that contribute to attitudes as a way of understanding behaviour (Home, 2003). Home 
suggests that when health behaviour involves decisions about treatment (e.g., such as 
taking medication) theoretical models should incorporate patient perceptions about 
treatment as well as perceptions about their illness. For this reason it was proposed 
that the CSM be extended to include a framework for understanding patients' 
perceptions about treatment; specifically, perceived need for medication and 
perceived concems about potential side effects (Home, 2003; Home & Weinman, 
2002). 
In Figure 3, the components of the CSM and addition of treatment perceptions 
are outlined. The numbered pathways show how the model can be used to explain 
medication taking behaviour. The model also highlights the importance of contextual 
Contextual factors e.g., self-efficacy, social and cultural norms, personality 
Perceptions of treatment e.g., needs and concerns 
Health 
Threat 
e.g., symptoms 
of information 
Emotional 
response to 
illness 
Coping 
procedure 
r 
Coping 
procedure 
Emotional response to treatment e.g., worry, fear 
Appraisal 
Appraisal 
Figure 3. Treatment Perceptions and the Common-Sense Model of Self-Regulation (from 
Home, 2003, p. 148). 
factors which influence a patient's perception of treatment and illness. The pathways 
can be explained as follows: (1) the severity of a patient's symptoms or information a 
patient may have about their illness {Health or Threat) will influence the patient's 
perceived need for or concerns about treatment {Perceptions of treatment)', (2) the 
processing of both the cognitive {Perceptions of treatment) and emotional aspects of 
treatment {Emotional response to treatment) occurs in parallel; (3) the patient strives 
for 'common-sense' coherence between their perceptions of illness and treatment, 
weighing up the necessity of treating the illness {Illness representation) with the 
concerns of treatment {Emotional response to illness) ; (4) patient perceptions of 
illness and treatment, influence coping in the form of adherence {Coping procedure); 
(5) the coping procedure (adherence or non-adherence) is evaluated in terms of it's 
effectiveness for the patient {Appraisal) which either reinforces or changes the 
patient's perceptions of treatment (see Home, 2003, p. 144-150 for further 
explanation). 
The CSM and the extended framework for understanding perceptions of 
treatment, has been used to understand adherence behaviour in areas such as 
preventative (e.g., asthma corticosteroid inhaler) medication management (Home & 
Weinman, 2002) and shows preliminary empirical support for the model in explaining 
adherence to highly active antiretroviral therapy (HAART) HIV treatment (Home, 
Cooper, Fisher, & Buick, 2001). 
REVIEW OF MEDICATION ADHERENCE INTERVENTIONS 
Given the high rates of non-adherence to antidepressant medication and the 
resulting negative consequences, it is not surprising that a number of interventions 
have been developed over the years to enhance adherence (Katon et al, 1999, 2001; 
Ludman et al., 2000; Mündt, Clarke, Burroughs, Brenneman, & Griest, 2001; 
Vergouwen, Bakker, Burger, Verheij, & Koerselman, 2005). However, non-adherence 
is not limited to depressive disorders, and a number of important adherence 
interventions have been designed for other chronic health conditions. Key among 
these has been Compliance Therapy (Kemp, Hayward, Applewhaite, Everitt, & 
David, 1996). Compliance Therapy aimed to influence adherence behaviour among 
patients with psychotic disorders through the use of motivational interviewing and 
other cognitive behavioural techniques. It was one of the first attempts to 
systematically evaluate a medication adherence intervention. In the Kemp et al. study, 
47 patients with a psychotic illness were randomly assigned to an intervention 
receiving 4 to 6 sessions of either Compliance Therapy or non-specific counselling. 
Treatment sessions were delivered by highly trained clinicians (a psychiatrist and 
clinical psychologist). Sessions were conducted twice a week and lasted between 20 
to 60 minutes. 
The content of Compliance Therapy consisted of a review and 
conceptualisation of the patients' illness and medication adherence problems. Next, 
specific discussions were conducted around issues such as side effects, the positive 
and negative consequences of taking medication, and the stigma of taking medication. 
Motivational interviewing techniques were conducted to explore ambivalence about 
taking medication and cognitive therapy techniques were used to challenge beliefs 
that impacted on adherence. Finally, self-efficacy was encouraged and the importance 
of maintenance treatment highlighted. Non-specific counselling consisted of the 
clinician listening to the patient's problems without discussion of treatment. 
Patients were sampled from 2in inpatient facility over a period of 8 months. All 
patients were diagnosed with a psychotic illness and all were taking antipsychotic 
medication. Twenty-two patients received Compliance Therapy and 22 received 
treatment as usual. All patients completed measures of symptom severity, insight, 
attitudes towards medication, social functioning, and self-reported adherence pre-
intervention, immediately after intervention, and 3 and 6 months post-intervention. 
Results showed that patients who received Compliance Therapy had 
significantly greater improvement than the non-specific supportive therapy group on 
measures of insight, attitude towards medication and adherence to medication after 
intervention and at 6 months post intervention (Kemp et al., 1996). However, 
Compliance Therapy showed no significant improvement in symptom severity over 
non-specific counselling. In a follow-up study, the effects found at 6 months post 
intervention were maintained over an 18-month period (Kemp, Kirov, Everitt, 
Hay ward, & David, 1998). While Compliance Therapy improves adherence to 
antipsychotic medication, it is limited by the need for highly trained clinicians to 
deliver the intervention. Furthermore, Compliance Therapy focused on the 
improvement of adherence to antipsychotic medication, not antidepressant 
medication. There are specific factors which influence adherence to antidepressant 
mediation (Unuetzer et al., 1999). Therefore it is unknown whether Compliance 
Therapy is suitable for patients with depressive disorders who are non-adherent to 
medication. 
In an attempt to improve outcomes among primary care patients with 
persistent depressive symptoms, Katon et al. (1999) evaluated a collaborative care 
intervention using a psychiatrist and patients' primary care physician. Participants 
were a group of 228 primary care patients, referred by their primary care physician 
who had been prescribed antidepressant medication. Patients were randomly assigned 
to the collaborative care intervention or usual care. 
Collaborative care interventions were delivered by a psychiatrist and a 
primary care physician. Patients met with the psychiatrist twice over a 4 week period. 
The first session was a 50 minutes assessment session. The second session was a 25 
minute follow-up session. The need for additional sessions was determined by patient 
response to treatment. The initial session with the psychiatrist included a review of 
illness, medical and social history, medication side effects and adherence. In addition, 
the psychiatrist liaised closely with the patient's physician to assist in the alteration of 
antidepressant dosage as required. Psychiatrists encouraged patients to engage in 
psychotherapy if severe psychosocial stressors were present. Specific medication 
adherence strategies used included education about antidepressant medication and 
consultation with the psychiatrist. Usual care involved the patient receiving an 
antidepressant medication prescription and visiting their physician two or three times 
for follow-up over the intervention period. 
Outcomes included medication adherence (based on self-report and data from 
prescription refills), satisfaction with care, and depression outcomes. Measurement 
occurred at 1, 3 and 6 months after patients were randomised to a treatment group. 
The intervention group showed significantly greater self-reported adherence, 
prescription refills, satisfaction with care, and depression outcomes, compared with 
the treatment as usual group (Katon et al., 1999). However, the researchers caution (1) 
that despite these effects, the collaborative nature of the intervention may be hard to 
implement in areas where primary care and specialist services are not well integrated 
and (2) patients included in the study were made available through referral and 
diagnosis determined by their physician, reducing the generalisability of these results 
to other patients with a diagnosable depressive disorder that may have been 
misdiagnosed (Katon et al.). The second caution should also be considered in light of 
the finding that primary care physician do not recognise approximately 50% of people 
who have a diagnosable mental health condition (Hickie et al., 2001). 
Ludman et al. (2000) aimed to enhance patients' use of antidepressant 
medication and depression outcomes over 12 months through the delivery of an 
intervention program that did not rely heavily on collaboration between practitioners 
and patients in primary care. In this intervention, cognitive behavioural strategies 
were used to address unrealistic beliefs about illness and treatment, and to highlight 
the benefits of medication adherence. Education was provided about side effects and 
early warning signs, to encourage help-seeking behaviour and self-management. 
Motivational interviewing was used to overcome resistance to medication use and to 
enhance motivation to engage in long-term adherence (e.g. 12 months). Follow-up by 
phone and mail was used to encourage medication and adherence and monitor self-
management. 
Participants were primary care patients who were identified as being at high 
risk for relapse, based on their history. A total of 386 patients participated in the 
study. Of these, 194 were randomly assigned to the intervention, while other 
participants received usual treatment from their primary care provider. The 
intervention was delivered over 12 months and consisted of two 30-minute videos and 
a self-care book that participants received one week prior to face-to-face contact. 
Face-to-face contact involved two 60-minute to 90-minute sessions, 2 to 4 weeks 
apart, with a depression specialist. Face-to-face consultation included the 
development of a relapse prevention plan, motivational interviewing, cognitive 
behavioural therapy, and education about antidepressant medication and depression. 
The depression specialist made contact (approximately seven contacts) with 
participants over the remainder of the intervention time every 4 to 8 weeks by phone 
or mail. This contact was intended to encourage medication adherence and self-
management. The depression specialists were a social worker, nurse, and a 
psychologist, who had been trained over two half-days by a psychologist, psychiatrist, 
and primary care physician. Depression specialists consulted with the psychiatrist 
bimonthly over the course of the intervention to review patients' relapse prevention 
plans and medication use. 
Self-report of adherence and depressive symptoms was obtained pre-
intervention and during phone contact with the depression specialist. The only formal 
measure of assessment used was the Beck Depression Inventory (Beck, Ward, 
Mendelson, Mock, & Erbaugh, 1961). Significant improvements in adherence and a 
reduction in depressive symptoms were obtained for the intervention group, compared 
with treatment as usual (Ludman et al., 2000). Ludman et al. concluded that this 
intervention was effective in enhancing adherence to medication and improving 
depression outcomes. This intervention required less direct patient contact from all 
practitioners involved (e.g. only by the depression specialist). However, the use of 
different practitioners in this study (e.g. the primary physician, psychiatrist and 
depression specialist) still relied heavily on extensive collaboration and 
communication among the highly trained providers. A final criticism is, like the 
Katon et al. (1999) study, the generalisability of these results to individuals with 
depressive disorders remains questionable given that diagnosis of depression was 
established by patients' primary care practitioner. 
Katon (2001) examined the effect of the intervention used by Ludman et al 
(2000) on a more representative sample of high-risk primary care patients with 
recurrent or chronic depression. With a focus on relapse prevention, Katon et al. 
examined adherence to medication, depressive symptoms, and risk of recurrence over 
a one-year period. Participants were randomly assigned to the intervention group or 
treatment as usual. Usual care included a prescription for antidepressant medication 
and between two to four follow-up visits with their physician. A total of 386 patients 
sampled from primary care settings were included in the study after an assessment of 
depression using the depression scales of the Structured Clinical Interview for the 
Diagnostic and Statistical Manual for Mental Disorders, 3rd edition revised (DSM-
m-R, APA, 1987) (Williams et al., 1992) and Hopkins Symptom Checklist (Derogatis, 
Rickels, Uhlenhuth, & Covi, 1974). Inclusion criteria were fewer than four symptoms 
of MDD and a history of three or more Major Depressive Episodes, which the 
researchers used to determine patients who had recovered but were at high-risk for 
recurrence. 
Adherence to medication, symptom severity, and recurrence was measured at 
3, 6, 9, and 12 months. Over the year, patients in the relapse prevention group were 
more likely to refill prescriptions for antidepressant medication and reported less 
severe depressive symptoms than those receiving usual care (Katon et al., 2001). 
However, no significant difference in reduction of the risk of recurrence was obtained 
for the intervention group. Katon et al. concluded that a more intensive intervention is 
required to reduce the risk of recurrence in patients with depression who have a high-
risk of recurrence. 
To provide comparison of the impact of an intensive (e.g. multi-strategy) 
versus a non-intensive adherence intervention Vergouwen et al. (2005) randomly 
assigned 211 primary care patients to either a non-intensive Follow-Up program {n = 
110) or an intensive Depression Care program (n = 101) over 26 weeks. Follow-up 
involved seven regular structured visits with a GP, with no specific strategies 
implemented by the GP to enhance adherence. The Depression Care program 
involved the same regular sessions with a GP and mail out of a newsletter to 
participants, (prior to each session with a GP), which provided information about 
medication, side effects, and the importance of adherence for up to 6 months. In the 
Depression Care group, the GP was instructed to discuss the benefits of adherence 
and to challenge perceived costs of adherence. The newsletters and sessions were 
designed to specifically target adherence by providing education about antidepressant 
medication and the importance of adherence, and by addressing participants' beliefs 
about treatment through discussion with the GP. 
Outcome measures included adherence (pill counts) and depressive symptom 
outcomes, assessed during GP visits at weeks 2, 6, 10, 14, 18, 22, and 26. Risk of 
relapse was not specifically measured. However, rates of remission were. Results 
revealed that no significant differences in adherence rates, depression outcomes, or 
rates of remission were found between the two interventions (Vergouwen et al., 
2005). Vergouwen et al. concluded that a less intensive, follow-up intervention 
appears to be as effective as a more intensive intervention for adherence and 
depression outcomes in primary care patients. However, the high frequency of visits 
used in these interventions is noted as a potential barrier to feasible treatment delivery 
in primary care (Vergouwen et al.). 
In a novel attempt to eliminate the need for clinicians to deliver adherence 
interventions, Mündt et al. (2001) examined the effect of an education only 
intervention on antidepressant medication adherence. Participants were 246 patients 
with MDD who had been prescribed antidepressant medication by their primary care 
physician. Participants were randomly assigned to the intervention group or treatment 
as usual. A total of 122 participants were included in the intervention group. The 
intervention included time-phased mail outs of information about recovery from 
depression and antidepressants directly to participants over a 7 month period. The 
researchers hypothesised that the education material would provide patients with 
sufficient support and information to encourage medication adherence, reduce 
depressive symptoms, and reduce risk of relapse (Mündt et al.). 
Participants completed measures of medication adherence (measured by 
monitoring prescriptions filled), depressive symptoms, social and work adjustment, 
and treatment satisfaction at 1, 3, and 7 months via telephone interviews. Results 
revealed no significant differences between the intervention and treatment as usual 
groups on measures of adherence to antidepressant medication, depression outcomes, 
and risk of relapse. The findings suggest that education alone as an intervention is not 
effective at enhancing adherence or reducing the risk of recurrence of depressive 
symptoms. This study highlights the need for adherence interventions that do not rely 
solely on education without clinical contact (Mündt et al., 2001) but instead 
incorporate a range of strategies to target adherence (Kemp et al., 1996). 
Overall, medication adherence interventions work to improve adherence to 
antidepressant medication and reduce depression symptom severity over a 6 to 12 
month period (Katon et al., 1999, 2001; Ludman et al., 2000; Vergouwen et al., 2005). 
Katon et al. (2001) suggest that more intensive interventions are required to determine 
how effective adherence interventions are at reducing the risk of recurrence. The 
utility of many of these more complex or intensive interventions is often limited by 
the need for highly trained clinicians (e.g., psychiatrists and physicians) to deliver the 
interventions (Byrne, Deane, Coombs, & Lambert, 2004). The inclusion of such 
highly trained clinicians in medication adherence interventions is not surprising, given 
that the responsibility for enhancing medication adherence has traditionally been seen 
as the domain of medical professionals such as primary care physicians, psychiatrists, 
and even nurses (Coombs, Deane, Lambert, & Griffiths, 2003). It has been suggested 
that given non-adherence is a common issue for primary care patients, the best way to 
address non-adherence would be to educate and train a range of health professionals, 
including allied health professionals, who provide services to primary care patients 
(Haley et al., 1998; McDaniel, Belar, Schroeder, Hargrove, & Freeman, 2002). 
Sawyer and Aroni (2003) suggest that adherence skills should be within the repertoire 
of the broad cross section of health clinicians, not only clinicians specialising in the 
pharmacological treatment of depressive disorders such as psychiatrists and 
physicians. Furthermore, significant outcomes in adherence and depressive symptoms 
can be achieved when such health professionals deliver adherence interventions 
(Katon et al., 2001; Ludman et al., 2000) 
EXPANDING THE SKILLS OF PRIMARY CARE CLINICIANS TO FACILITATE 
MEDICATION ADHERENCE 
Expanding the range of clinicians who provide adherence strategies to patients 
in primary care is of particular importance within an Australian context. The capacity 
to refer people with depression to psychological services has been expanded in 
Australia under a raft of new government initiatives. Examples of these include the 
Better Outcomes in Mental Health Care Program (2001 - 2005) and the Medicare 
funded initiative Enhanced Primary Care. In November 2006 the Australian 
Government announced funding of $538 million over 5 years to expand Medicare and 
improve access to psychological services for individuals with a mental illness. This 
enables patients to receive psychological services covered under Medicare. It is 
important to note that while psychologists are one of the targeted professions to 
provide these services, a range of allied health clinicians provide primary care 
services to individuals with depressive disorders in Australia. One example of this 
occurs in community health centres that employ a team of allied health clinicians to 
provide primary care services. Within the centres, the term allied health clinician 
often refers to psychologists, social workers, occupational therapists, and mental 
health nurses. 
There is considerable debate about whether psychologists should provide 
medication-related services to patients (Walters, 2001). This is complicated by the 
debate regarding whether psychologists should obtain prescription rights (Walters). 
Overall, there is little data or commentary related to the role that allied health 
clinicians should assume with regard to supporting medication adherence. Westerfelt 
(2004) argues that allied health workers, such as social workers, should be encouraged 
to facilitate patient adherence by encouraging patients to communicate with their 
physician about their medication use and by providing patients with information about 
their medication. Similarly, it has also been argued that psychologists are well 
equipped to provide services that assist patients in their use of medication. In a 
discussion of the collaboration that psychologists often have with their patients and 
other health professionals, Weene (2002) states that psychologists already have many 
skills that may be useful in facilitating medication adherence among their patients. 
These include the ability to; deliver psychoeducation, develop a trusting therapeutic 
relationship, monitor adherence, assess problems, and collaborate with other health 
care providers (e.g., physicians). 
There is limited data available on the practices of psychologists pertaining to 
their involvement in the facilitation of adherence. Bascue and Zlotowski (1980) found 
that 10% of psychologists in their US sample (N = 137) did not know if their patients 
were taking medication, 23% stated they did not get involved in the facilitation of 
medication use, and 6% believed that medication should not be used as a treatment for 
depression. In a more recent survey, 96% of psychologists reported they were seeing 
at least one patient who had been prescribed medication (VandenBos & Williams, 
2000). Of these psychologists, 43% of the patients on their caseloads were receiving 
psychotropic medication. While 99% of the psychologists indicated that they would 
make a referral for medication evaluation or consultation, only 73% reported that they 
do so routinely. Although 73% is a high rate of psychologists reporting they routinely 
refer patients for medication evaluation or consultation, they reported doing so for 
only up to 25% of their patients. Given that 43% of patients were receiving 
medication, it does not appear that such referrals were routine practice for the 
psychologists. Furthermore, 16% of psychologists said that they did not discuss 
medication issues during therapy with any of their patients (VandenBos & Williams). 
These findings are somewhat concerning as they suggest that many psychologists do 
not routinely engage in strategies to facilitate patient adherence to medication and 
some psychologists do not get involved in facilitating adherence at all. 
Clinicians' Beliefs about Medications and their Role in Facilitating Medication 
Adherence 
In seeking to understand why clinicians don't use adherence strategies some 
researchers have examined the role of the clinician's own beliefs upon their clinical 
behaviour. Many researchers suggest that clinician beliefs about medication treatment 
may influence the type of treatment the patient will receive, including whether they 
receive help to use their medication more effectively (Byrne, Deane, & Coombs, 
2005; Farris & Schopflocher, 1999; Ramstrom, Afandi, Elofsson, & Petersson, 2006; 
Stern et al., 1999). Byrne et al. found that general beliefs about medications, as 
measured by the Beliefs about Medicines Questionnaire (Home, Weinman, & 
Hankins, 1999), predicted how effectively nurses indicated they were able to use 
adherence strategies. Specifically they found that self-rated difficulty implementing 
specific adherence strategies was influenced by both a lack of knowledge about 
medication and negative beliefs about medication (Byrne et al.). 
Ramstrom et al. (2006) found 51% of pharmacists agree that medications are 
overused and that this belief may be a barrier to communication with patients. 
Furthermore, pharmacists self-efficacy (self confidence) beliefs about their ability to 
facilitate patient adherence has been found to be a direct predictor of pharmacist 
behaviour, specifically that low confidence is a barrier to providing adequate 
pharmaceutical care (Farris & Schopflocher, 1999). This is an important finding given 
that self-efficacy, a person's beliefs about their ability and confidence to perform a 
specific behaviour (Bandura, 1977), is reported to be a consistent predictor of 
engagement in that behaviour (Bandura, 1977, 1997; Brannon & Feist, 2000). 
Finally, Stem et al. (1999) found that 36% of psychologists and 54% of social 
workers in their sample considered antidepressant medication to be somewhat 
ineffective as a treatment option and they recommended that future research examine 
a possible link between beliefs about medication and subsequent referral for an 
appropriate medical review. Together these studies suggest clinicians' beliefs about 
medication and their ability to facilitate adherence (including confidence, self-
efficacy, and adequacy) may be related to the extent to which clinicians will engage in 
behaviours that facilitate adherence (Byrne et al., 2005; Farris & Schopflocher, 1999; 
Ramstrom et al., 2006). 
Beliefs about antidepressant medication being helpful are associated with 
knowledge of depression and professional experience in dealing with depressive 
disorders (Jorm, Christensen, & Griffiths, 2005). This is demonstrated by the 
significant difference in beliefs among different health professionals about whether 
antidepressant medication is helpful for people with depressive disorders (Jorm et al., 
2005; Jorm, Korten, Jacomb, Rodgers, & Pollitt, 1997). For example, Jorm et al. 
(1997) report that 89% of clinical psychologists identify antidepressant medications as 
being helpful. In comparison, a survey of the Australian public revealed that only 
25% of individuals (who were not clinically trained but who identified themselves as 
having experience working with individuals with depressive disorders) reported 
antidepressant medications as being helpful (Jorm et al., 2005). The significant 
difference between beliefs about the effectiveness of antidepressant medication may 
in part be associated with different levels of knowledge and experience (Jorm et aL, 
2005). 
In more recent studies it has been found that many health clinicians do not 
appeeir to have received adequate training in adherence strategies and lack the 
requisite skills and knowledge, or do not hold the necessary beliefs to support 
adherence (Coombs et aL, 2003; Byrne et aL, 2004, 2005). This is despite evidence 
that these elements can be enhanced (Byrne et aL, 2004; Gray, Wykes, & Goumay, 
2003). As previously noted, it is imperative that a range of health clinicians develop 
the appropriate knowledge and skills in this much needed area, given that there are a 
diverse range of health professionals providing primary health care services to 
individual with depressive disorders in Australia. 
Effects of Medication Adherence Training on Clinicians' Knowledge, Skills, and 
Beliefs 
In the UK, Gray et al. (2003) evaluated the effectiveness of Medication 
Management, a training program that enhances community mental health nurses' 
(CMHN) clinical skills to a level necessary for the delivery of Compliance Therapy 
(Kemp et aL, 1996). As previously reported. Compliance Therapy is an intervention 
program designed to enhance medication adherence among individuals with psychotic 
disorders (Kemp et aL). The Gray et al. (2003) study involved training 52 CMHNs 
over 10 days in areas such as individualised assessment, cognitive therapy skills, and 
psychopharmacology. Evaluation of the training revealed CMHNs achieved 
significant increases in clinical skills and knowledge. In a follow-up study, the 
patients of nurses who received training reported greater adherence to prescribed 
medication and less psychopathology compared to patients receiving treatment as 
usual (Gray, Wykes, Edmonds, Leese, & Goumay, 2004). The researchers concluded 
that Medication Management training was an effective means of enhancing CMHNs 
skills and knowledge to an adequate level for potential delivery of Compliance 
Therapy (Gray et al., 2003) and that this training improved clinical outcomes for 
patients with schizophrenia (Gray et al., 2004). 
The research conducted by Gray et al. (2004) is promising for expanding the 
skills of clinicians to facilitate adherence, but there are three issues that need to be 
addressed to enhance the efficacy and feasibility of training; (1) clinician beliefs need 
to be assessed and targeted during training, (2) a 10-day training program for 
clinicians is not feasible within Australian primary care settings, and (3) future studies 
need to be broadened to include a wider range of allied health clinicians treating 
people with mental health issues in Australia, not just nurses who are often assumed 
to have the main role in the facilitation of medication adherence (Coombs et al., 
2003). 
Surguldaze, Timms, and David (2002) addressed two of these issues (i.e. the 
length of the training program and lack of focus on clinician beliefs) by developing a 
shorter, 2-day version of Compliance Therapy training that specifically aimed to 
increase trainees' understanding of adherence issues, skills to engage with and 
manage patients with a psychotic disorder, attitudes towards patients with psychosis 
who are non-adherent, and beliefs about the facilitation of adherence. Participants 
were 73 psychiatrists in training, 19 of whom received the modified Compliance 
Training and 54 served as a control group. 
Pre- and post-training measures comprised questions about the causes of non-
adherence, consequences of non-adherence, rating of skills important for building a 
collaborative relationship with and managing patients with a psychotic illness, beliefs 
about the management of psychosis, and attitudes towards non-adherence. After 
training, psychiatric trainees reported a significant increase in their ability to identify 
the causes and consequences of non-adherence and confidence in their skills to 
manage patients with psychosis (Surguldaze et al., 2002). This increase was 
significantly higher than those reported in the control group. However, no significant 
increases in ratings of skills important for building a collaborative relationship with 
patients with a psychotic illness, beliefs about the management of psychosis, or 
attitudes towards non-adherence were obtained over the course of training 
(Surguldaze et al.). It is important that clinicians' hold the necessary beliefs to 
facilitate medication adherence as such beliefs can influence whether or not clinicians 
will engage in strategies to facilitate medication adherence (Byrne et al., 2005; Farris 
& Schopflocher, 1999; Ramstrom et al., 2006; Stem et al., 1999). 
MEDICATION ALLIANCE 
In an effort to capture the essential ingredients of Medication Management 
(Gray et al., 2003) and Compliance Therapy (Kemp et al., 1996) while addressing 
their shortcomings, Byrne et al. (2004) developed Medication Alliance for delivery in 
Australian primary care services. Medication Alliance is a training program designed 
to enhance the skills, knowledge, and beliefs of clinicians working with individuals 
who have been prescribed medication and who are non-adherent. In its original form 
(Byrne et al.) it is a 3-day training program for mental health clinicians working with 
individuals with psychosis who are non-adherent to medication. 
The program comprises several features of previous medication adherence 
programs (Gray et al., 2003; Kemp et al., 1996), as well as additional strategies 
suggested as being effective in enhancing adherence, but which were lacking in 
previous training programs. These core components include; developing a therapeutic 
alliance, individualised assessment, cognitive interventions, motivational interviewing 
and problem solving. It was modelled largely from Medication Management and was 
developed in consultation with Medication Management researchers (Gray et al.). A 
copy of the Medication Alliance program as used in Byrne et al. (2004) can be found 
on the appended CD-ROM file Medication Alliance training program topics. 
Medication Alliance Core Components 
Therapeutic Alliance 
Horvath (2000) notes that for any form of change to occur in therapy, a 
positive therapeutic alliance is vital. A strong therapeutic alliance helps to develop 
trust and creates an environment in which an individual can feel safe and secure 
enough to explore behaviour change (Horvath). As conceptualised by Bordin (1979), 
the therapeutic alliance describes the relationship between the therapist and patient, 
comprising of the development of an emotional bond and the agreement of tasks and 
goals in therapy. Bond is the emotional side of the alliance, comprising relational 
qualities such as trust, respect, and caring. The agreement of tasks within therapy 
involves a mutual understanding of issues related to the type of task, timing and 
structure of activities. Agreement of goals emphasises the necessity of a mutual 
agreement of the therapy goals including an agreement on the investment in and 
achievement of the goals. 
The importance of developing a strong therapeutic alliance is well established 
given that regardless of other treatment variables, it is found to be a consistent 
predictor of positive outcomes in therapy (Ellis & Smith, 2002; Howgego, 
Yellowlees, Owen, Meldrum, & Dark, 2003; Martin, Garske, & Davis, 2000). 
Similarly, in a number of studies, the therapeutic alliance has been found to predict 
adherence to medication regimes. For example, therapeutic alliance was the most 
consistent predictor of adherence to antipsychotic medication among outpatients with 
psychotic disorders, compared with other variables thought to influence adherence 
(Weiss, Smith, Hull, Piper, & Huppert, 2002). The importance of alliance in treatment 
adherence is supported by numerous authors (Delgado, 2000; Demyttenaere, 1997; 
Frank, 1997). However, there has been a lack of focus on developing a therapeutic 
alliance in previous medication adherence intervention programs. In an attempt to 
incorporate the development of a therapeutic alliance as part of training, Surguldaze et 
al. (2002) measured the effects of Compliance Therapy on psychiatric trainees' 
confidence in their skills to develop an alliance with their patient. No impact on 
psychiatric trainees' confidence to build a therapeutic alliance was obtained over the 
course of training. 
Medication Alliance incorporates the importance of developing a strong 
therapeutic alliance by focusing on the agreement of tasks and goals during therapy 
(Bordin, 1979). This is achieved during Medication Alliance training in the following 
ways (see Medication Alliance training with people who have depressive disorders: 
Training manual file on the appended CD-ROM, p.68-84, p.99-113, pl59-161); 
• Normalising medication non-adherence 
• Developing an understanding of what non-adherence is 
• Developing an understanding of what some of the specific medication 
adherence issues are for individuals with depressive disorders 
• Identifying the specific factors that influence adherence 
• Encouraging the sharing of information about medication and non-
adherence between clinician and patient 
• Developing empathy among clinicians for non-adherence issues 
• Setting an agenda with the patient which involves an agreement 
between clinician and patient about what therapy will focus on and 
what each individuals roles will be 
Individualised Assessment 
There are many factors that can influence an individuals' adherence to 
medication. Therefore, treatments need to be tailored to the individual's specific 
adherence needs. Furthermore, individualised treatment is an excellent way to foster 
alliance and helps to enhance adherence to medication (Marland & Cash, 2001). In 
order for individualised treatment to occur, an individualised assessment needs to be 
conducted to identify all the possible causal variables influencing medication non-
adherence (Haynes & Williams, 2003). Once the causal variables are identified, 
individualised treatment planning can begin. 
One type of individualised assessment strategy is 2i functional analysis 
(Haynes, Leisen, & Blaine, 1997; Haynes & WiUiams, 2003). Functional analysis 
allows for the identification of the function of a specific behaviour (such as not taking 
medication) by gathering information about antecedents and consequences of the 
behaviour (Tustin, 1993). As standard treatments may not be effective for some 
patients with multiple problem behaviours, the functional analysis enables important 
causal variables of behaviour to be identified so the most effective treatment can be 
administered (Haynes & Williams, 2003). A causal relationship between two 
variables is said to occur when "(a) they co vary (i.e., when one changes, so does the 
other), (b) the causal variable reliably precedes the dependent variable (i.e., the 
problem behaviour), (c) there is a logical connection, (d) alternative explanations for 
covariance can be excluded" (Haynes et al., 1997, pp. 334). 
A functional analysis of behaviour is essential in the conceptualisation of 
hypotheses regarding cause, maintenance and treatment (Truax, 2001). Conducting a 
functional analysis to identify the cause of non-adherence allows treatment planning 
to focus specifically on the cause for non-adherence. However, there is a lack of 
research into medication adherence programs that emphasise the need for such an 
individualised assessment. This is despite the fact that individualised assessment is 
recommended as an essential part of providing treatment (Truax). 
Medication Alliance uses individualised assessment to help clinicians identify 
specific causes for medication non-adherence adherence. This is achieved during 
Medication Alliance training in the following ways (see Medication Alliance training 
with people who have depressive disorders: Training manual file on the appended 
CD-ROM, p.l 14-122, p.164-185); 
• Finding out what the medication adherence problems are through the 
use of an illness timeline (a structured way of reviewing with the 
patient times when medication was adhered to and not adhered to and 
identifying proximal factors that may have influenced adherence) 
• Using functional analysis and case formulation to determine the most 
likely causal factors of medication adherence, given the information 
collected in the illness timeline 
Cognitive Therapy 
Cognitive therapy (Beck, 1964; Beck, 1995) is a structured psychological 
intervention used to identify and modify dysfunctional thoughts, beliefs and 
behaviours of an individual so as to produce a change in emotions and behaviour. It is 
goal orientated and problem focused. In its original form (Beck, 1964) cognitive 
therapy was designed to treat depression. Over the years, cognitive therapy has been 
modified and adapted for use with a range of psychopathology. However, the 
underlying principle of cognitive therapy remains the same. That is, "distorted or 
dysfunctional thinking (which influences the patient's mood and behaviour) is 
common to all psychological disturbances" (Beck, 1995, pp. 1). 
Dysfunctional thoughts and beliefs are first identified and then a series of 
different strategies are used to modify these in order to facilitate guided discovery of 
more helpful thoughts and beliefs to bring about emotional and behavioural change 
(e.g. take medications) (Beck, 1995). This is achieved by using a range of strategies to 
reduce the conviction with which a thought or belief is held by evaluating them, and 
then replacing the thought or belief with a more helpful, realistic ones (Beck, 1995). 
Modification of patient beliefs about taking medication is an important component in 
Medication Alliance training given that these beliefs have been significantly 
associated with medication adherence (Aikens et al., 2005; Home & Weinman, 1999). 
Brown et al. (2005) identified specific beliefs that influence antidepressant 
medication adherence among primary care patients by administering the Beliefs about 
Medicines Questionnaire (Home et al., 1999) to a sample of 192 patients. The 
findings showed that 51% of patients believe antidepressant medication is overused, 
27% believe doctors place too much trust in medications, 23% believe most 
medications are addictive, 49% are concerned about the long-term side effects of 
medication, and 37% worry about becoming dependant on their medication. 
Cognitive therapy has been used successfully to modify patient beliefs about 
taking medication in previous medication adherence interventions (Gray et al., 2004; 
Kemp et al., 1996). In the Gray et al. (2004) study, nurses who had been trained (see 
Gray et al., 2003) in specific cognitive therapy interventions such as identifying 
patient beliefs about medication and challenging these beliefs through guided 
discovery, were more effective in improving patient attitudes towards antipsychotic 
medication and medication adherence. Kemp et al. demonstrated that through the use 
of cognitive strategies, patients with psychotic disorders showed significant increases 
in their attitudes towards antipsychotic medication, insight into their illness, and 
adherence to medication. These strategies used included (adapted from Kemp et al., p. 
346); 
Reviewing the patient's illness history 
Conceptualising the problem of adherence 
Discussion about symptoms and side effects of treatment 
Processing the benefits and drawbacks of medication 
Exploring the patient's ambivalence 
Highlighting discrepancies between the patient's actions and beliefs 
Focusing on adaptive behaviours 
Encouraging self-efficacy 
Discussing the value of staying well and thus the need for maintenance 
of medication 
During Medication Alliance training, cognitive therapy is used to challenge 
and modify patient beliefs about medication and adherence issues in order to facilitate 
prescribed adherence to antidepressant medication. Knowledge of specific 
antidepressant medication beliefs such as those reported by Home et al. (1999) can be 
used to specifically tailor cognitive therapy strategies. In addition to the strategies 
used in the Kemp et al. (1996) study, the cognitive strategies used in Medication 
Alliance training include (see Medication Alliance training with people who have 
depressive disorders: Training manual file on the appended CD-ROM, p.202-218); 
• Discussing thoughts, feelings, and beliefs that concern patients about 
their medication usage 
• Developing an understanding of the cognitive model and how 
thoughts, feelings and behaviours interact 
• Developing clinician ability to identify thoughts and beliefs about 
medication and medication adherence 
• Understanding and normalising distorted thinking styles 
• Increasing and assessing doubt about the validity of thoughts and 
beliefs 
• Gathering evidence to challenge beliefs 
• Identifying alternative thoughts and beliefs that are more facilitative of 
medication adherence 
Motivational Interviewing 
Motivational interviewing is a directive yet patient-centred technique for 
increasing problem recognition and enhancing motivation to change (Miller & 
Rollnick, 1991, 2002). By using interviewing strategies such as reflective listening 
and direct questions the clinician can help the patient to develop an awareness of the 
discrepancies between their current problem behaviour (e.g. not taking medication) 
and their values or goals (e.g. being well) (Burke, Arkowitz, & Menchola, 2003). 
The goal of motivational interviewing is to enhance the patient's perspective 
of the importance of changing their behaviour to reach a desired outcome (e.g. 
adhering to medication to reduce symptoms and the risk of relapse). To do this, it is 
important for the patient and not the clinician to develop reasons for change (Burke et 
al., 2003; Miller & Rollnick, 1991). This goal is reached by the clinician utilising five 
basic principles of motivational interviewing (1) expressing empathy, (2) developing 
discrepancies, (3) avoiding argumentation, (4) rolling with resistance, and (5) 
encouraging self-efficacy (Miller & Rollnick). 
Motivational interviewing has been used extensively in adherence 
interventions and is regarded as an effective strategy for enhancing adherence (Kemp 
et al., 1996; Ludman et al., 2000; Rusch & Corrigan, 2002; Zygmunt, Olfson, Boyer, 
& Mechanic, 2002), Kemp et al. found that patients with psychosis, who had received 
Compliance Therapy, which has significant motivational interviewing components, 
demonstrated more positive attitudes towards medication, enhanced insight into 
illness, and increased adherence to antipsychotic medications than those treated with 
non-specific counselling. Specific motivational interviewing strategies used in 
Compliance Therapy included identifying the costs and benefits of taking medication 
and exploring patients' ambivalence to take medication, and developing discrepancies 
between their current medication taking behaviour and their beliefs. Similarly, 
Ludman et al. used motivational interviewing strategies, such as rolling with 
resistance, exploring ambivalence, and developing discrepancies, as a significant 
component in their adherence intervention to significantly increase patients' 
adherence to antidepressant medication. 
Motivational interviewing is used in Medication Alliance training to help 
patients reach a point where they can understand the importance of medication 
adherence in reaching personally relevant goals. This is achieved during training in 
the following ways (see Medication Alliance training with people who have 
depressive disorders: Training manual file on the appended CD-ROM, p.85-98, 
p. 186-201); 
• Understanding the patient's level of motivation to take medication 
and/or resistance to medication adherence (including what is 
resistance, how is it shown, and where does it come from) 
Developing skills to discuss medication adherence with resistant or 
unmotivated patients 
Exploring and building patient importance and confidence in 
medication adherence 
Understanding when to roll with resistance and when to encourage 
motivational change in order to preserve therapeutic alliance 
Exploring ambivalence, weighing up the good and bad things about 
medication adherence, and helping patients to 'tip the scales' towards 
medication adherence behaviour 
Problem Solving 
Problem solving is a technique used to assist individuals in identifying 
alternative ways of dealing with problems during everyday life (Chang & D'Zurilla, 
1996). Chang and D'Zurilla's problem solving outcomes are achieved through the two 
processes of problem orientation and problem solving proper. Problem orientation is 
related to how an individual thinks or conceptualises their everyday life problems and 
how they perceive their own problem-solving ability, while problem solving proper 
refers to the process of identifying alternative solutions to problems in an attempt to 
find a solution that is the most likely to lead to a desired outcome (Chang & 
D'Zurilla). Problem solving proper is often used in medication adherence 
interventions as a strategy to identify problems with taking medication and 
developing solutions to overcome barriers (Kemp et al., 1996; Miklowitz, George, 
Richards, Simoneau, & Suddath, 2003). 
Providing patients with problem solving strategies to overcome adherence 
issues has been noted as an important strategy in a review of effective adherence 
intervention programs for people with schizophrenia (Zygmunt et al., 2002). In a 
randomised study of outpatient management of bipolar disorder, patients who 
received an intervention incorporating problem solving skills showed better 
medication adherence over 2 years than patients receiving a less intensive, crisis 
management intervention (Miklowitz et al., 2003). The specific problem solving 
strategies used were identifying a problem specific to treatment management, 
brainstorming solutions, evaluating the advantages and disadvantages of each 
solution, and choosing a solution to implement (Miklowitz et al.). 
Problem solving is used in Medication Alliance training to help patients 
overcome practical problems that impede medication adherence. This is achieved 
during training in the following ways (see Medication Alliance training with people 
who have depressive disorders: Training manual file on the appended CD-ROM, 
p.123-143, p.219-220); 
• Defining the problem; using the problems identified during 
individualised assessment 
• Generating alternative solutions to the problem 
• Looking at the disadvantages and advantages of each solution and 
weighing up the alternatives 
• Encouraging the patient to choose the alternative that best suits them 
• Helping patients to make detailed plans of how to execute the solution 
• Encouraging patients to implement and evaluate the success of the 
alternative solution through the use of systematic homework 
Clinician Outcomes from the Medication Alliance Training Program 
Byrne et al. (2004) delivered the program to 23 mental health workers in 
Tasmania who were working with individuals with psychosis. The sample comprised 
19 mental health nurses, 2 psychologists, 2 social workers, and 1 unreported 
professional designation. Training included both didactic and interactive teaching 
techniques, with time allowed for skill practice and role-plays. Measures taken pre-
and post-training were used to assess changes in skills, knowledge, and beliefs over 
the course of training. A number of measures were developed in order to assess 
training outcomes. All measures were pencil-and-paper measures with the exception 
of the Cognitive Therapy Scale for Psychosis, which was videotaped and blind-rated. 
The Medication Alliance Cognitive Therapy Scale for Psychosis (based on the 
Cognitive Therapy Scale for Psychosis^ Haddock et al., 2001) was developed to assess 
video-taped segments of participants' demonstrating skills in delivering a range of 
Medication Alliance strategies including agenda setting, problem solving, cognitive 
challenging of medication beliefs, motivational interviewing, and homework. 
The Functional Analytic Case Formulation was developed to measure how 
effectively participants could identify causal variables of non-adherence. The measure 
included a vignette which described a patient who was non-adherent to antipsychotic 
medication. Imbedded in the vignette were a number of causal variable for non-
adherence that participants had to identify. 
Changes in knowledge were assessed using the Medication Alliance Clinician 
Knowledge Questionnaire. This is a 15-item multiple-choice questionnaire asking 
participants about the ways in which medication adherence can be influenced 
(through the use of Medication Alliance strategies). 
The Medication Alliance Beliefs Questionnaire (MABQ) was used to assess 
participants beliefs related to working with individuals who are non-adherent to 
medication. Twenty-two items are rated on a 5-point Likert scale (1 = Strongly 
Disagree" to 5 = Strongly Agree"), with higher responses indicating more positive 
beliefs. Subscales of the MABQ included Adequacy, Legitimacy, Motivation, Work 
Satisfaction, and Self Esteem. 
The Elsom Therapeutic Optimism Scale (Elsom, 2002) was used to measure 
participants' optimism about medication as an effective treatment option for patients. 
Comparison of pre- and post-training outcomes showed that Medication 
Alliance training significantly increased clinician knowledge about medication 
adherence issues and knowledge of the strategies that can be used to facilitate 
adherence. In addition, skills to effectively enhance medication adherence, and 
specific beliefs about clinicians' adequacy, work satisfaction, and optimism about 
working with individuals who are non-adherent were all improved (Byrne et al., 
2004). The relative brevity of Medication Alliance in comparison to other medication 
adherence interventions (Gray et al., 2003) also increased it's feasibility for delivery 
within Australian primary care settings. 
However, the intervention focused only on clinicians who identified 
themselves as having a legitimate role in facilitating adherence (Coombs et al., 2003). 
A weakness in the Byrne et al., (2004) study is that it failed to account for clinicians 
for whom facilitating adherence is not a typical role. Addressing the knowledge, 
skills, and beliefs of a range of mental health clinicians is important, given that many 
clinicians (e.g. allied health clinicians) are working with individuals under primary 
health care initiatives in Australia (e.g. Better Outcomes in Mental Health Care and 
Enhanced Primary Care) who may be nonadherent. Furthermore, this training 
focused on enhancing clinicians' knowledge, skills, and beliefs, related to facilitating 
adherence among patients with psychosis; it is not known if this training program is 
effective at enhancing the knowledge, skills, and beliefs of allied health clinicians 
working with patients with depressive disorders who are non-adherent to 
antidepressant medication. 
The Present Study 
Patients with depressive disorders are commonly referred by primary care 
physicians to specialist allied health services, such as psychological services. While 
psychologists provide the majority of these services, a range of allied health clinicians 
provide primary care services to individuals with depressive disorders in Australia. As 
a result, allied health care providers are often in a position to support or facilitate the 
adherence of patients to antidepressant medication in primary care environments. 
However, there is a dearth of information about the current medication adherence 
practices of allied health clinicians in Australia who work with primary care patients 
with depressive disorders. Specifically, it is unclear whether allied health 
professionals view facilitation of medication adherence as part of their role. 
Furthermore, it is unclear whether a broader range of clinicians, such as allied health 
clinicians, can be trained in medication adherence interventions, given that previous 
interventions have generally required highly trained clinicians to deliver such 
programs (Kemp et al., 1996) or have only trained with clinicians who are perceived 
as having a role in facilitating adherence (Byrne et al., 2004; Gray et al., 2003). 
This research sought to identify the extent to which allied health clinicians 
believe helping patients adhere to their medication is a role in which they should 
engage and the extent to which they use specific adherence strategies (Study 1). 
Furthermore, this study examined the impact of a modified Medication AUiance 
training program on clinicians' knowledge, skills, and beliefs related to facilitating 
medication adherence among individuals with depressive disorders (Study 2). 
STUDY 1: 
PRIMARY CARE ALLIED HEALTH CLINICIANS' VIEWS OF THEIR ROLES 
IN FACILITATING ANTIDEPRESSANT MEDICATION ADHERENCE AND 
PREDICTORS OF ADHERENCE STRATEGY USE 
It was hypothesised that beliefs about medication, beliefs about allied health 
professionals' role in facilitating adherence, adequacy (self-efficacy), and previous 
training in specific medication adherence strategies would be related to the extent to 
which allied health clinicians working with primary care patients report using specific 
medication adherence strategies. It is expected that previous training, more positive 
beliefs about medication, beliefs that allied health clinicians have a role in facilitating 
adherence, and higher adequacy, will be associated with greater self-reported use of 
specific strategies to enhance adherence. The degree to which these variables predict 
self-reported use of specific strategies was also explored. 
Method 
Participants and Procedure 
Participants were 72 allied health clinicians (i.e., psychologists, social 
workers, occupational therapists) working with primary care patients. To ensure 
participants were delivering services to primary care patients, specific questions about 
the context of their clinical work were asked. Participants who satisfied this criterion 
were those who indicated they were (a) working in a primary care setting such as a 
Division of General Practice or community health centres, and/or (b) providing 
services under a primary care program (e.g., Better Outcomes in Mental Health Care 
and/or Enhanced Primary Care). A convenience sample of participants was accessed 
via mail or face-to-face delivery of surveys. Psychologists working in private practice 
in the South Eastern Sydney and Illawarra areas were accessed via mail from 
addresses listed in the Yellow Pages. Psychologists on a nation-wide mailing list held 
by the Australian Psychological Society were also accessed via mail. Individuals on 
this list had previously consented to being contacted for research distributed by the 
Australian Psychological Society. Primary care agencies in the South Eastern Sydney 
and Illawarra Area Health Service were contacted to arrange a time to visit and leave 
surveys for allied health clinicians to complete. In return for involvement in the study, 
participants were offered the opportunity to enter a draw for a book voucher. Separate 
reply paid envelopes were provided to return their book voucher entries to ensure that 
surveys remained anonymous. 
A total of 212 surveys were distributed; 101 were mailed out following 
identification in the Yellow Pages, 61 were mailed out via the APS mailing list, and 
50 were delivered directly to primary care agencies. Eighty-eight surveys were 
returned, giving a response rate of 41.5%. Eighteen surveys were excluded from the 
analysis because 14 participants did not indicate they were currently working within a 
primary care context, and 4 participants indicated they were non-allied health 
professionals (e.g. physicians or nurses). Thus, the following analyses were based on 
72 participants who met entry criteria. Most participants were female (75%, n = 54). 
The mean age of participants was 42.6 years (range 22 to 69 years). Participants 
included 54 psychologists (75%), 12 social workers (16.7%), and 6 occupational 
therapists (8.3%). The average length of time that participants had worked in their 
profession was 11.4 years (range 0 to 37 years). The majority of participants (76.4%, 
n = 55) worked 30 or more hours per week in their profession. Participants were 
mostly from NSW [(90.3%, n = 65, with the remainder from VIC (2.8%), QLD 
(2.8%), WA (1.4%), and ACT (1.4%)]. 
Thiry-one participants (43.1%) identified themselves as working with patients 
through the Better Outcomes in Mental Health Care program, while 34 (47.2%) 
reported that they were working with patients through the Enhanced Primary Care 
initiative. Of these, 16 participants (22.2%) identified themselves as working with 
patients through both the Better Outcomes in Mental Health Care program and 
Enhanced Primary Care initiative. Cognitive behavioural therapy was reported as a 
model of therapy used by 27 participants (37.5%), while 27 participants (37.5%) 
reported using eclectic or integrated models. Other models of therapy reportedly used 
were existential psychology, rehabilitation models and personal construct 
psychotherapy (13.9%). Eight participants (11.1%) did not report the type of therapy 
model they used. Places of work were reported as private practice (44.5%), 
community health centres (37.5%), community mental health centres (23.6%), 
hospitals (4.2%), and 'other' (2.8%). There was some overlap of places of work, with 
13.9% of participants identifying themselves as working in both community based 
and private practices. There was missing data for the place of work for one participant 
(1.4%). The average number of patients on participants' active case loads was 28 
(range 1 to 100). 
Materials 
See Appendix A for a copy of the survey used in this study. The survey had 
four sections: (Section A) demographic and background details, (Section B) general 
beliefs about medication, (Section C) general beliefs about adequacy to facilitate 
adherence, and (Section D) specific beliefs about facilitating adherence among 
individuals with depressive disorders who are non-adherent to antidepressant 
medication. 
Section B included the 8-item General scale of the Beliefs about Medicines 
Questionnaire (Home et al., 1999: BMQ). Items are rated on a 5-point Likert scale (1 
= ''Strongly Disagree'', 2 = ''Disagree'', 3 = "Uncertain", 4 = "Agree" to 5 = 
"Strongly Agree"), with higher scores indicating more negative beliefs. The items 
provide two subscales. Overuse and Harm. The Overuse subscale consists of four 
items (score range 4 to 20) to examine the extent to which the clinician believes 
doctors overuse medications {"Doctors use too many medications", "Natural remedies 
are safer than medications", "Doctors place too much trust on medications ", and "If 
doctors had more time with patients they would prescribe fewer medications"). The 
Harm subscale also consists of four items (score range 4 to 20) to identify the extent 
that the clinician believes medications are harmful or poisonous {"People who take 
medications should stop their treatment for a while every now and again", "Most 
medications are addictive", "Medications do more harm than good', and "All 
medications are poisons"). 
Home et al. (1999) found satisfactory internal consistency (Cronbach alpha 
coefficients) for the Overuse subscale in samples of general medical inpatients {n = 
90, a = .60) asthmatic patients {n = 78, a = .74), diabetic {n = 99, a = .80), renal {n = 
47, a = .77), cardiac (w = 116, a = .74), and psychiatric patients {n = 89, a = .73). 
Mixed intemal consistency was found for the Harm subscale among diabetic (a = 
.66), renal (a = .83), psychiatric (a = .70), general medical (a = .51), asthmatic 
patients (a = .47), and cardiac patients (a = .51). Intemal consistency was improved in 
later research with 600 undergraduate students, by assigning the item ''Natural 
remedies are safer than medications'" to the Harm subscale and excluding the item 
"A// medications are poisons'" (Home et al., 2004). Alpha values for this modified 
version were a = .72 and a = .62 for the Overuse and Harm subscales respectively. 
Ramstrom et al. (2006) also used this modification in their sample of 141 pharmacy 
patients and 136 pharmaceutical specialists, obtaining alpha values of a = .65 and a = 
.70 for the Overuse and Harm subscales respectively. 
Using the original 4-item Overuse and 4-item Harm subscales (Home et al., 
1999), sufficient intemal consistency for research purposes was obtained in the 
present study; a = .66 (Overuse) and a = .67 (Harm). When the changes used by 
Home et al. and Ramstrom et al. (2006) were applied in the present study, intemal 
consistency was not significantly improved; a = .70 (Overuse) and a = .63 (Harm), 
Therefore, the original 4-item Overuse and 4-item Harm subscales (Home et al.) were 
retained. Taking the Overuse and Harm subscales as a total scale revealed higher 
intemal consistency (a = .76). The Overuse and Harm subscale were used initially for 
detailed analyses. The total scale was used for correlation and regression analyses. 
Test-retest correlations of the Overuse and Harm scales have been reported at .60 and 
.78 respectively (Home et al). Home et al. report that both subscales distinguish 
between the beliefs of patients attending community pharmacies and those attending 
non-medical clinics. Correlation between the subscales was reported at .40 (Home et 
al.). 
Section C included the 6-item Adequacy subscale from the 22-item Medication 
Alliance Beliefs Questionnaire (MABQ). The MABQ explores clinician beliefs about 
working with individuals who are non-adherent to medication (Byrne et al., 2004). 
The questionnaire was originally adapted from ih& Alcohol and Alcohol Problems 
Perception Questionnaire (Gorman & Cartwright, 1991) to assess clinician attitudes 
to working with alcohol problems. Similar adaptations of the measure have been used 
to assess clinician beliefs about working with individuals with psychosis (McLeod, 
Deane, & Hogbin, 2002). The main modification of the questionnaire involved 
replacing words related to ''drinking or alcohol use'' with ''medication adherence 
issues'' (Byrne et al.). 
Items are rated on a 5-point Likert scale (1 = "Strongly Disagree", 2 = 
"Disagree", 3 = "Uncertain", 4 = "Agree" to 5 = "Strongly Agree"), with higher 
responses indicating more positive beliefs. The Adequacy subscale total score ranges 
from 6 to 30 and reflects how effectively the clinician believes they are able to help 
individuals with medication adherence issues based on their knowledge and skill (e.g., 
"I feel that I can appropriately advise people about the use of their medications"). 
Cronbach alpha for the Adequacy scale has been reported at a = .83 in a sample of 
292 mental health clinicians (Byrne, Deane & Caputi, 2006). In a previous version of 
the Adequacy scale, Cronbach alpha was reported at .77 in a sample of 77 mental 
health clinicians (McLeod et al., 2002). In the present study Cronbach alpha was a = 
.87. 
Section D contained items specific to working with individuals with 
depressive disorders who are taking antidepressant medication. Items were generated 
by the researchers for the purposes of this study. Participants were asked to report the 
number of patients with depressive disorders on their caseload who are non-adherent 
to prescribed antidepressant medication. They were then asked to rate the question 
"How true is it that patients who are non-adherent to antidepressant medication 
occupy more of your time than those who are adherent to antidepressant 
medication?''. This was rated on a 10-point Likert scale (1 = ''Not At All True'' 
through to 10 = ''Completely True"). 
The researchers developed a 3-item Effectiveness scale to assess participants' 
beliefs about how effective antidepressant medication is as a treatment for depressive 
disorders (e.g., "Antidepressant medication is an effective treatment for depressive 
disorders"). Ratings were provided on a 5-point Likert scale (1 = "Strongly Disagree" 
to 5 = "Strongly Agree"). The total score range for the Effectiveness scale was 3 to 15, 
with higher scores indicating more positive beliefs about medication being an 
effective treatment for depressive disorders. In the present study Cronbach alpha was 
a = .69. A 2-item Role scale was developed to assess whether participants believe that 
facilitating their patients' use of antidepressant medication is an appropriate 
professional activity for them or not (e.g., "Helping patients adhere to antidepressant 
medication is an appropriate professional activity for me"). Ratings were provided on 
a 5-point Likert scale (1 = "Strongly Disagree" to 5 = "Strongly Agree"). The total 
score range for the Role scale was 2 to 10, with higher scores indicating more positive 
beliefs about helping with medication adherence being an appropriate professional 
activity. In the present study Cronbach alpha was a = .88. 
An 11-item Strategy Use scale was developed by the researchers from 
previously research (see Byrne et al., 2005) to gauge the extent to which clinicians 
reportedly used a variety of different strategies to help patients with their use of 
medication (e.g., "I ask my patients to monitor their medication adherence", "I 
encourage my patients to speak to their physician about medication adherence"). The 
11 items on the Strategy Use scale were rated on a 5-point Likert scale (1 = "Not At 
All", 2 = "A Little Bif, 3 = "Sometimes", 4 = "Often", to 5 = "Almost Always"). The 
total score range for the Strategy Use scale was 11 to 55, with higher scores indicating 
greater reported use of specific strategies to help with patient adherence. In the 
present study Cronbach alpha was a = .89. 
Finally, participants were asked if they had received any specific training on 
how to enhance medication adherence, and if so, to provide details of the training (e.g. 
number of hours of training, format of training). 
Results 
Statistical analyses were performed using the Statistical Package for the 
Social Sciences (SPSS) for Windows (v. 15.0) (SPSS Inc., 2006). Participants reported 
that an average of 45.7% (range 4% to 95%) of the patients on their caseload had a 
depressive disorder. Of these patients, 63.9% (range 3% to 100%) had been 
prescribed antidepressant medication, and of these 26.7% (range 0% to 80%) were 
non-adherent to prescribed antidepressant medication. On a scale assessing whether 
patients who are non-adherent to antidepressant medication occupy more time than 
those who are adherent, participants reported an average of 4.8 (where 1 = ''Not At All 
True'' to 10 = ''Completely True''). Approximately 40% of these participants reported 
a score of 6 or greater. 
The majority of participants (63.9%, n = 46) reported that they have not 
received any specific training on how to enhance medication adherence. Of the 26 
participants (36.1%) who reported they had received training, the majority (61.5%, n 
= 16) received 8 hours or less of training. The range of training varied widely between 
2 hours to 720 hours of training delivered in the format of workshops, reading, and 
experience gained "on the job". 
Table 2 
Means (M), Standard Deviations (SD,) and Ranges for the Overuse, 
Harm, Adequacy, Effectiveness, Role and Strategy Use Scales (N = 72) 
Scales M SD Range 
Overuse 12.29 2.92 4 - 20 
Harm 7.49 2.28 4 - 20 
Adequacy 21.76 4.15 6 - 30 
Effectiveness 10.86 1.67 5 - 15 
Role 7.67 1.82 2 - 10 
Strategy Use 38.90 8.40 11--55 
Table 2 outlines the means, standard deviations, and ranges of the variables 
used in the analyses (e.g.. Overuse, Harm, Adequacy, Effectiveness, Role, and 
Strategy Use scales). Higher scores on the Overuse and Harm subscales indicate more 
negative beliefs about the overuse and harmfulness of antidepressant medication, 
respectively. Higher scores of the Adequacy subscale indicate more positive beliefs 
about adequacy to help individuals with medication adherence issues. Higher scores 
of the Effectiveness scale indicate more positive beliefs about the effectiveness of 
antidepressant medication as a treatment for depressive disorders. Higher scores on 
the Role scale indicate more positive beliefs about facilitating medication adherence 
being an appropriate professional activity. Higher scores on the Strategy Use scale 
indicate greater reported use of specific adherence strategies to help with patient 
adherence. 
Table 3 
Percentage of Responses for Items in the Overuse and Harm Subscales of the BMQ 
(N=72) 
Subscales and items 
Disagree/ 
Strongly 
Disagree Uncertain 
Agree/ 
Strongly 
Agree 
Overuse 
"Doctors use too many medications" 26.8 18.3 54.9 
"Natural remedies are safer than 
medications" 
65.3 27.8 6.9 
"Doctors place too much trust on 
medications" 
21.1 15.5 63.4 
"If doctors had more time with patients 
they would prescribe fewer medications" 
19.7 28.2 52.1 
Harm 
"People who take medications should 
stop their treatment for a while every now 
and then" 
66.2 25.3 8.5 
"Most medications are addictive" 85.9 11.3 2.8 
"Medications do more harm than good" 84.5 12.7 2.8 
"All medications are poisons" 88.9 6.9 4.2 
Note. On a scale of 1 - 5, "'Disagree!Strongly Disagree" = 1 and 2, respectively; '"Uncertain" = 3; 
"'Agree!Strongly Agree" - 4 and 5, respectively. 
Table 3 outlines participants' responses for both the Overuse and Harm 
subscales of the BMQ. Response ratings presented in Table 3 were organised into 
three categories for descriptive purposes; those disagreeing {''Disagree" and ''Strongly 
Disagree''), those rating ''Uncertain", and those agreeing CAgree'' and ''Strongly 
Agree"). Overall, most participants agreed that medications are overused and 
disagreed that medications are harmful. Almost 50% of participants did not agree or 
were uncertain that doctors would prescribe less medication if they had more time 
with patients. Over 90% of participants disagreed with or were uncertain about the 
statement "Natural remedies are safer than medications". One third of participants 
were uncertain or agreed that people should stop their treatment for a while every now 
and then. 
The response ratings for the Adequacy subscale of the MABQ are reported in 
Table 4. Response ratings presented in Table 4 were organised into three categories 
for descriptive purposes; those disagreeing {"Disagree" and "Strongly Disagree"), 
those rating "Uncertain", and those agreeing {"Agree" and "Strongly Agree"). 
Overall, the majority of participants believed that they could adequately facilitate 
medication adherence. However, approximately 50% of participants disagreed or 
were uncertain that they could appropriately advise patients about their medication 
use. Almost 50% did not agree that they knew enough about the risk factors for 
developing medication adherence problems. Over 30% of participants reported that 
they were not satisfied with the way they work with people with medication 
adherence issues. 
Table 5 outlines the response rates for the Effectiveness and Role scales. There 
was missing data for two participants for the Effectiveness scale. The missing data 
was replaced with item means of the total remaining sample of participants 
(Tabachnick & Fidell, 2001). Response ratings presented in Table 5 were organised 
into three categories for descriptive purposes; those disagreeing {"Disagree" and 
"Strongly Disagree"), those rating "Uncertain", and those agreeing {"Agree" and 
Table 4 
Percentage of Responses for the Items in the Adequacy Subscale of the MABQ 
(N=72) 
Item 
Disagree/ 
Strongly 
Disagree Uncertain 
Agree/ 
Strongly 
Agree 
"I feel I know enough about the reasons why 
people don't use medications" 12.5 11.1 76.4 
"I feel I know how to counsel people who 
have medication adherence issues over the 
long term" 
11.1 15.3 73.6 
"I feel that I can appropriately advise people 
about the use of their medications" 31.0 18.3 50.7 
"I feel that I have a working knowledge of 
medication adherence issues" 
8.4 8.5 83.1 
"On the whole I am satisfied with the way I 
work with people who have medication 
adherence issues" 
8.3 23.6 68.1 
"I feel I know enough about the factors 
which put people at risk of developing 
problems with the use of their medications" 
12.7 35.2 52.1 
Note. On a scale of 1 - 5, ''Disagree/Strongly Disagree" = 1 or 2, respectively; ''Uncertain" = 3; 
"Agree!Strongly Agree" = 4 or 5, respectively. 
''Strongly Agree"). Overall, participants agreed that antidepressant medication is an 
effective treatment for depressive disorders. However, almost 75% did not agree that 
depressed patients taking antidepressant medication will get better. While most 
participants indicated that facilitating adherence is an appropriate professional activity 
for them to engage in, 30% of participants did not agree or were uncertain. 
Table 5 
Percentage of Responses for Items in the Effectiveness and Role Scales (N = 72) 
Scale and item 
Disagree/ Agree/ 
Strongly Strongly 
Disagree Uncertain Agree 
Effectiveness 
"Antidepressant medication is an 8.6 
effective treatment for depressive 
disorders" 
"Antidepressant medication helps to 0.0 
reduce the symptoms of depressive 
disorders" 
"Depressed patients who take 21.4 
antidepressant medication will get better" 
Role 
"Helping patients adhere to 12.7 
antidepressant medication is an 
appropriate professional activity for me" 
"It is appropriate for clinicians without 7.0 
medical training to assist patients with 
medication adherence" 
17.1 
11.4 
52.9 
16.9 
15.3 
74.3 
88.6 
25.7 
70.4 
77.9 
Note. On a scale of 1 - 5, "Disagree/Strongly Disagree" = 1 or 2, respectively; "Uncertain" - 3; 
"Agree!Strongly Agree" = 4 or 5, respectively. 
Table 6 outlines the response rates for the Strategy Use scale. Response 
ratings presented in Table 6 were organised into three categories for descriptive 
purposes; those reporting they do not regularly use adherence strategies C^otAtAir 
and "A Little''), those reporting they ''Sometimes'' use adherence strategies, and those 
reporting they regularly use adherence strategies COften" and ''Almost Always"). The 
Table 6 
Percentage of Responses for the Strategy Use Scale Items (N= 72) 
Items 
Not At Often/ 
All/ Almost 
A Little Sometimes Always 
"I do not get involved with my patient's 22.3 
medication adherence" 
"I use specific interventions to enhance 30.6 
medication adherence" 
"I consult with a physician about my 23.6 
patient's medication adherence" 
"I discuss medication adherence issues with 8.3 
my patients" 
"I enquire about medication side effects 2.8 
with my patients" 
"I ask my patients to monitor their 26.4 
medication adherence" 
"I provide patients with information about 33.3 
medication" 
"I assess the possible causes of my patient's 20.9 
medication non-adherence" 
"I provide motivational strategies to help 26.4 
my patients with adherence to medication" 
"I encourage my patients to speak to their 2.8 
physician about medication adherence" 
"I use problem solving strategies to 22.2 
overcome medication non-adherence" 
31.9 
33.3 
27.8 
20.8 
8.3 
27.7 
20.9 
13.8 
22.2 
8.3 
30.5 
45.8 
36.1 
48.6 
70.9 
88.9 
45.9 
45.8 
65.3 
51.4 
88.9 
47.3 
Note. On a scale of 1 - 5, ''Not At All!A Little" = 1 or 2, respectively; ''Sometimes" - 3; "Often/Almost 
Always" = 4 or 5, respectively. 
most common strategies reported as being used regularly by participants to facilitate 
medication adherence include discussing adherence issues with patients, enquiring 
about side effects, assessing the possible causes of non-adherence, and encouraging 
patients to speak to their physician about medication adherence. Only 50% of 
participants reported that they regularly use motivational interviewing strategies to 
facilitate adherence. Approximately 50% of participants report that they do not 
regularly (as indicated by a response of''Not At AW\ "A Little'' and ''Sometimes'') 
provide information about antidepressant medication, use problem solving strategies 
to overcome adherence problems, or ask their patients to monitor their adherence. 
Impact of Previous Training on Beliefs and Strategy Use 
A series of between group i-tests were used to determine if previous training 
had any impact on beliefs about medication (taking the Overuse and Harm subscales 
as a total scale; Overuse+Harm), Adequacy, Effectiveness, Role, and Strategy Use 
scales. The means and standard deviations of these variables for participants who had 
received prior training in medication adherence strategies compared with those who 
had not are reported in Table 7. All assumptions for conducting i-tests were met. The 
results of the between group i-tests are shown in Table 7. 
A total of 63.9% of participants reported that they had not received prior 
training in medication adherence strategies and 36.1% reported that they had. The t-
test results revealed that participants who had received prior training had significantly 
(a) lower levels of beliefs that medications in general were overuse and harmful, (b) 
more positive beliefs about adequacy to facilitate adherence, (c) more positive beliefs 
about the effectiveness of antidepressant medication as a treatment for depressive 
Table 7 
Means (M), Standard Deviations (SD) and t-Test Statistics (t)for the Overuse+Harm, 
Adequacy, Effectiveness, Role, and Strategy Use Scales for Participants Who Had 
Received Prior Training Compared to Those Who Had Not (N =72) 
Prior training 
(n = 26) 
No prior 
training 
in = 46) 
Scales 
M SD M SD t P 
Overuse+Harm 8.87 2.30 10.47 2.11 2.92 .003** 
Adequacy 23.31 3.60 20.89 4.23 -2.57 007** 
Effectiveness 11.37 1.58 10.57 1.63 -2.06 .022* 
Role 8.54 1.30 7,17 1.90 -3.60 .001** 
Strategy Use 42.35 6.79 36.96 8.66 -2.92 .003** 
* Significant at /? < .05 (1-tailed) 
** Significant at p < .01 (1-tailed) 
disorders, (d) more positive beliefs about facilitating medication adherence being an 
appropriate professional activity, and (e) higher self-reported use of specific strategies 
to enhance adherence, than those who had not received prior training. 
Relationship Between Beliefs and Self-Reported Strategy Use 
Pearson's correlation was used to examine the relationship between beliefs 
about medication (Overuse+Harm), beliefs about Adequacy, beliefs about the 
Effectiveness of antidepressant medication, beliefs about facilitating medication 
adherence being an appropriate professional activity {Role), and the extent of self-
reported use of specific strategies to enhance adherence {Strategy Use). All variables 
used in the analysis met the assumptions of normality. Pearson's correlations are 
reported in Table 8. See Table 2 for the means and standard deviations for the 
variables. 
Results showed that the total score of the Strategy Use scale was negatively 
correlated with Overuse+Harm scale. This indicates that the more participants 
believed medications to be overused and harmful, the less they reported using 
strategies to facilitate adherence. Adequacy was found to correlate positively with 
Strategy Use, such that more positive beliefs about adequacy were associated with 
higher reported use of strategies to facilitate adherence. Effectiveness was found to 
correlate positively with Strategy Use, such that more positive beliefs about the 
effectiveness of antidepressant medication were associated with higher reported use of 
strategies to facilitate adherence. Role was found to correlate positively with Strategy 
Use, such that more positive beliefs about facilitating medication adherence being an 
appropriate professional activity were associated with higher reported use of strategies 
to facilitate adherence. 
Role correlated negatively with the Overuse+Harm scale indicating that more 
positive beliefs about facilitating medication adherence being an appropriate 
professional activity were associated with more positive beliefs about the overuse and 
Table 8 
Pearson Correlations (r) between Overuse+Harm, Adequacy, Effectiveness, Role, 
and Self-Reported use of Strategies (Strategy Use) to Facilitate Adherence (N =72) 
Scales Strategy Use Role Effectiveness Adequacy 
Overuse+Harm -.37** -.47** -.31* -.18 
Adequacy .61** .48** .42** — 
Effectiveness .48** .52** — 
Role .65** — 
* Significant at p < .01 (1-tailed) 
** Significant at/? < .001 (1-tailed) 
harmfulness of antidepressant medications. Role correlated positively with Adequacy 
indicating that more positive beliefs about facilitating medication adherence being an 
appropriate professional activity were associated with more positive beliefs about 
adequacy. Role also correlated positively with Effectiveness indicating that more 
positive beliefs about facilitating medication adherence being an appropriate 
professional activity were associated with more positive beliefs about the 
effectiveness of antidepressant medication. 
Effectiveness correlated negatively with the Overuse+Harm scale indicating 
that more positive beliefs about the effectiveness of antidepressant medication were 
associated with more positive beliefs about the overuse and harm of antidepressant 
medications. Effectiveness correlated positively with Adequacy indicating more 
positive beliefs about the effectiveness of antidepressant medication were associated 
with more positive beliefs about adequacy. No significant correlation was found 
between Adequacy and the Overuse+Harm scale. 
Factors Predicting Self-Reported Strategy Use 
The final analysis was a standard multiple regression to determine which 
factors (e.g., Overuse+Harm, Adequacy, Effectiveness, Role, and prior training) 
predict Strategy Use when all variance is accounted for. The assumptions of normality 
for the variables used in the multiple regression were met. Tolerance levels were not 
found to be excessively low. No bivariate correlations were found to be over .70. The 
results for the multiple regression are presented in Table 9. 
Results revealed that the regression model was significant, accounting for 52% 
of the variance in strategy use (F(5) = 16.39, p = .000; R^ = .55 and adjusted R^ = .52). 
When all variance was accounted for, Role and Adequacy remained consistent 
predictors of self-reported Strategy Use, This suggests that clinicians' greater 
perceived adequacy and more positive beliefs that facilitating medication adherence is 
an appropriate professional activity, predicted higher self-reported use of specific 
adherence strategies. 
Table 9 
Summary of Multiple Regression for Scales Predicting Strategy Use (N =72) 
Scales B SEB P p 
Overuse+Harm -.35 .35 -.10 .162 
Adequacy .75 .20 .37 .000* 
Effectiveness .51 .51 .10 .159 
Role 1.70 .52 .37 .001* 
Prior Training .29 1.58 .02 .427 
Note. Adjusted R^ = .52 
** Significant atp < .01 (1-tailed) 
Discussion 
This study identified the views of primary care allied health clinicians about 
their role in facilitating adherence among patients with depressive disorders, and 
predictors of their self-reported use of adherence strategies. 
Allied health clinicians in the study report a large proportion of their patients 
with depressive disorders are prescribed antidepressant medication (64%) and almost 
27% (ranging from 0% to 80% non-adherence) of these patients are non-adherent to 
their prescribed antidepressant medication. This high rate of non-adherence is 
comparable to the high rates of non-adherence among primary care patients reported 
in previous research (see Aikens et al., 2005; Lin et al, 1995; Simon et al., 1993). 
While most clinicians do not believe that patients with medication adherence issues 
take up more time in session than patients who do not have these issues, the high rates 
of non-adherence among patients suggests that there is a need for clinicians to spend 
time facilitating medication adherence among their patients. 
Given this need, it is encouraging that most clinicians believe facilitating 
medication adherence is an appropriate professional role in which to engage and they 
believe that they can adequately facilitate medication adherence. However, 30% do 
not agree with or are unsure about whether facilitating medication adherence is an 
appropriate professional role in which to engage. Approximately 50% of clinicians do 
not agree that they can appropriately advise patients about their medication use. 
Almost 50% indicate that they do not know enough about the risk factors for 
developing medication adherence problems and over 30% are not satisfied with the 
way they work with people with medication adherence issues. Furthermore, it is 
concerning that over 60% of clinicians have not received any prior training on how to 
facilitate medication adherence. This lack of training has been identified in previous 
research, highlighting that many health clinicians do not appear to have received 
adequate training in medication adherence strategies (Coombs et al., 2003; Byrne et 
al., 2004, 2005). 
A lack of previous training, disagreement about the appropriateness of 
facilitating adherence, and clinicians' beliefs about their inadequacy to facilitate 
adherence suggests that primary care allied health clinicians should be provided with 
more opportunities to develop their ability to facilitate adherence. This is highlighted 
by the finding that clinicians who had previously received adherence training reported 
more positive beliefs about medication, adequacy, effectiveness of antidepressants, 
and facilitating adherence being an appropriate professional activity in which to 
engage. This has important implications for clinical practice as greater perceived 
adequacy and acceptance that facilitating adherence is an appropriate professional 
activity predict higher self-reported use of specific adherence strategies. 
There is a need for a structured approach to training as the quality of prior 
training appears difficult to evaluate. This is due to the diversity and inconsistency of 
training methods (workshops, reading, and experience gained "on the job") and hours 
(between 2 hours to 720 hours) that clinicians who have had training report receiving. 
Almost 75% of allied health clinicians indicated that they agree with the 
statement ''Antidepressant medication is an effective treatment for depressive 
disorders". Conversely, some scepticism was observed in 75% of clinicians 
disagreeing with the statement ''Depressed patients who take antidepressant 
medication will get better''. Most clinicians believe that medications are overused but 
do not believe that medications are harmful. In this study, 55% of clinicians believe 
that medications are overused compared with reports that only 51% of patients believe 
that medications are overused (Brown et al., 2005). Similarly, 63% of clinicians in 
this study believe that doctors place too much trust in medications compared with 
only 27% of patients (Brown et al.). These findings suggest that allied health 
clinicians may be more sceptical than patients about the use of medication. 
Patients who are sceptical about the use of medication demonstrate the lowest 
rates of adherence to antidepressants (Aikens et al. 2005) which raises the question 
about the potential role of clinician scepticism on the facilitation of adherence. The 
belief that medications are overused has been found among 51% of pharmacists and 
has been suggested as a barrier to effective communication between pharmacists and 
patients (Ramstrom et al., 2006). Furthermore, clinician scepticism about the use of 
medication has been suggested as an influence on the type of treatment patients 
receive, including whether they receive support from their clinician to use their 
medication more effectively (Byrne et al., 2005; Ramstrom et al., 2006; Stem et al., 
1999). The importance of ensuring that clinician's develop facilitative beliefs about 
working with adherence issues is highlighted by the many useful strategies in which 
clinicians can engage to facilitate adherence. 
Clinicians indicate that they regularly discuss adherence issues with patients, 
enquire about side effects, assess the possible causes of non-adherence, and encourage 
patients to speak to their physician about medication adherence as strategies to 
facilitate adherence. Interestingly, strategies that have been shown to effectively 
influence patient medication adherence were reported to be regularly used by only 
50% of the clinicians. Such strategies include motivational interviewing (Kemp et al., 
1996; Ludman et al., 2000; Rusch & Corrigan, 2002; Zygmunt et al., 2002), providing 
information about antidepressant medication (as part of Cognitive Therapy, see 
Aikens et al., 2005; Home & Weinman, 1999), problem solving (Miklowitz et al., 
2003; Zygmunt et al., 2002), and asking patients to monitor their adherence (as part of 
developing a therapeutic alliance, see Weiss et al., 2002; as part of individualised 
assessment, see Truax, 2001). This indicates that 50% of clinicians report that they do 
not regularly use these important strategies to facilitate adherence. 
This study showed that clinicians who had previously received training in 
medication adherence strategies were more likely to report that they believe 
medications are not harmful or overused, have a higher sense of adequacy in 
facilitating adherence, believe antidepressant medication is an effective treatment for 
depressive disorders, believe that facilitating adherence is an appropriate professional 
activity in which they can engage, and use more strategies to facilitate adherence. 
This further supports the need for training of primary care allied health clinicians 
given that (a) the majority of clinicians in this study (64%) and in previous research 
report that they have not received previous training (Coombs et al., 2003; Byrne et al., 
2004, 2005), and (b) clinicians' beliefs can be enhanced by such training (Byrne et al., 
2004). 
Correlation analyses show that self-reported engagement in strategies to 
facilitate adherence is related to clinicians' beliefs about medication and working with 
adherence issues. Clinicians were most likely to report engaging in strategies to 
facilitate adherence if they believed that medications were not harmful or overused, 
held positive beliefs about their adequacy to facilitate adherence, believed that 
antidepressant medication is an effective treatment for depressive disorders, and 
believed that facilitating adherence is an appropriate professional activity in which 
they can engage. Multiple regression analysis revealed that when all variance is 
accounted for, more positive beliefs about adequacy and facilitating adherence being 
an appropriate professional activity predict higher self-reported use of adherence 
strategies. As the results from this study and previous research show, clinicians' 
beliefs about the use of medication influence the treatment that patients receive, such 
that more positive beliefs are associated with more regular engagement in strategies to 
facilitate adherence (Byrne et al., 2005; Farris & Schopflocher, 1999; Ramstrom et 
al., 2006). Furthermore, the results from this study are supported by previous findings 
that report clinicians' beliefs about adequacy to facilitate adherence are a direct 
predictor of behaviour, such that more positive beliefs about adequacy are associated 
with more regular engagement in strategies to facilitate adherence (Bandura, 1997; 
Farris & Schopflocher, 1999). A novel finding of this study is that more positive 
beliefs about whether facilitating adherence is an appropriate professional activity in 
which to engage is also a predictor of higher self-reported use of adherence strategies. 
This finding has implications for professional degree programs where clarification of 
professional roles around supporting medication use may need to be improved. 
The generalisability of these findings to all allied health clinicians is limited 
given that the sample was predominately psychologists. However, these findings 
provide important information about the current practices of psychologists delivering 
services in primary care. Since being introduced, there has been an extremely high use 
of government funded psychological services by primary care patients. There have 
been a number of media releases (e.g. by the Australian Psychological Society) about 
the higher than expected uptake, suggesting that over time, more patients are going to 
be referred by primary care physicians and seen by psychologists. The proportion of 
other allied health professional groups working in primary care is not known and 
should be addressed in future research to ensure generalisability of these findings to 
all allied health clinicians, not just psychologists. Finally, as this study relied on self-
report of clinicians' beliefs and behaviours it is difficult to determine whether these 
findings are a true reflection of clinicians' actual beliefs and work practices. 
In summary, this study identified that allied health clinicians working in 
primary care believe that facilitating patient adherence to antidepressant medication is 
an appropriate professional role in which they can engage. The extent to which they 
engage in such strategies is influenced by ih&ii beliefs about medications, beliefs 
about adequacy to facilitate adherence and prior training in medication adherence 
strategies. The findings suggest that primary care allied health clinicians should 
receive structured training in facilitating medication adherence among patients with 
depressive disorders to enhance their skills, knowledge, and beliefs necessary to 
facilitate adherence. 
STUDY 2: 
TRAINING CLINICIANS TO FACILITATE ADHERENCE TO 
ANTIDEPRESSANT MEDICATION AMONG INDIVIDUALS WITH 
DEPRESSIVE DISORDERS 
This study examined the delivery of an adapted Medication Alliance program 
(Byrne et al., 2004) for allied health clinicians working with individuals with 
depressive disorders who are non-adherent to antidepressant medication. The impact 
of training on clinician (1) knowledge of medication adherence issues and ways to 
facilitate adherence, (2) skill to use a specific medication adherence strategy 
(identifying causal variables for non-adherence), and (3) beliefs about working with 
individuals who are non-adherent and beliefs about the use of medication, was 
explored. Modifications to the original program (Byrne et al., 2004) included; (1) a 
change in training content to ensure training specifically covered the issues related to 
facilitating adherence among individuals with depressive disorders and, (2) a 
reduction in adherence training time from 3 days to 2 days for Medication Alliance 
training. 
It was hypothesised that the modified Medication Alliance training program 
would significantly enhance clinician knowledge, skill and beliefs to facilitate 
adherence among individuals with depressive disorders. Examination of the effect of 
training on clinicians' general beliefs about the use of medication was of an 
exploratory nature and no predictions were made. 
Method 
Participants 
Participants were recruited for the study via poster advertisement in their 
places of work (primary care offices within Southern Health, Victoria's largest 
metropolitan health service). The advertisement stated that the training was part of 
voluntary workplace training. Interested clinicians were invited to register for training 
(contact details were supplied on the advertisement poster). No inclusion criteria were 
applied. Participants were nurses and allied health clinicians involved in the Better 
Outcomes in Mental Health Care program, and allied health clinicians from a primary 
mental health team. One participant in private practice was included in the training. 
A total of 24 clinicians participated in the training, and 22 provided 
demographic information. Eight were psychologists (36%), 6 social workers (27%), 6 
nurses (27%), 1 occupational therapist (5%), and 1 research fellow (5%). Of the 
participants who gave demographic information, 17 were female (77%). The mean 
age of participants was 40.71 years (range 23 to 59 years). The average length of time 
working in their current profession was 13.86 years (range 1 to 40 years) and the 
average length of time employed in their profession specifically in a mental health 
setting was 10.21 years (range 1 to 26 years). Three participants (14%) stated they had 
not previously worked in a mental health setting. 
Nineteen participants (86%) reported they had active caseloads and were all 
working with patients with a depressive disorder. Participants reported 91.6% (range 
of 30% - 100%) of their patients with depressive disorders were taking antidepressant 
medications. Of these patients, 23.3% (range 0% - 75%) were variable in their 
medication adherence. Only four participants (18%) reported they had previously 
received training specifically related to medication adherence issues. 
Materials and Procedure 
Training consisted of a 3-day workshop facilitated by the researcher (DF) and 
one of the trainers from the original Medication Alliance workshops (Byrne et al., 
2004). The first day of training provided participants with a review of information 
regarding the nature of depressive disorders and the current assessment tools and 
treatment options available. This was followed by two days of Medication Alliance 
training. An outline of the Medication Alliance workshop program (days 2 and 3) is 
shown in Table 10. The reduction of Medication Alliance training to two days is 
significant in terms of feasibility of delivery, given that the original program was 
delivered over three days (Byrne et al., 2004). The additional day of training (day 1) 
was incorporated into the program given the diverse range of health professionals 
involved in the training to ensure adequacy of knowledge of depressive disorders 
prior to Medication Alliance training. This additional information was adapted from 
the Mental Health Aptitudes into Practice (MAP) training programs 
(http://www.bevondblue.org.au) (Monash University & Beyondblue: The National 
Depression Initiative, 2004a,b). Material covered during day 1 of training was not 
assessed in the pre- or post- training evaluation. 
The workshop incorporated didactic teaching, demonstration of skills and 
opportunity for participants to practice skills in small groups. Training was facilitated 
according to a series of power point slides, supported by an adapted version of the 
original Medication Alliance training manual (Byrne et al., 2003). An overview of the 
Table 10 
Overview of Medication Alliance Training Program (Days 2 and 3 of Training) for 
Individuals with Depressive Disorders 
Medication Alliance Technology: An Introduction 
Normalising non-adherence 
What is non-adherence? 
What influences adherence? 
The clinician role in medication adherence 
Engagement 
Agenda Setting, Information Sharing, Normalising Rationales, Empathy 
Assessment 
Illness Timeline, Functional Analysis <& Case Formulation 
Therapy 
Motivational Interviewing strategies, Cognitive Behavioural strategies (for 
thoughts, feelings and concerns about medications). Problem Solving and 
Homework 
Evaluation 
Homework 
Integration of Core Concepts 
content of the original Medication Alliance training program was elaborated earlier 
(pp. 36 - 49). The adapted version for this study (Byrne & Feros, 2004a, see 
appended CD-ROM file Medication Alliance with people who have depressive 
disorders: Training manual) included content changes to ensure training material 
reflected issues relevant for working with individuals with depressive disorders as the 
original program (Byrne et al., 2003; Byrne et al., 2004) had a focus on working with 
individuals with psychosis. Training covered a range of techniques previously found 
to be effective in the enhancement of medication adherence including motivational 
interviewing, cognitive behavioural strategies, and problem solving skills (Gray et al., 
2003; Kemp et al., 1996). Also included was a focus on variables found to 
consistently predict adherence including the patient-clinician relationship (Delgado, 
2000; Demyttenaere, 1997), and addressing patient beliefs that are barriers to 
medication adherence (Aikens et al., 2005). Participants were provided with 
workshop booklets that included a copy of all power point slides and handouts used 
during the workshop to demonstrate skills (Byrne & Feros, 2004b, see appended CD-
ROM file Medication Alliance with people who have depressive disorders: Trainee 
resource book 1, 2, and 3). 
Measures 
All measures were taken at the beginning of the first day of training (pre-
training) and were repeated at the end of the last day of training (post-training). See 
Appendix B for a copy of the pre-training measures. 
Knowledge 
The Medication Alliance Clinical Knowledge Questionnaire is a 15-item 
multiple-choice questionnaire. Questions were adapted from a previous knowledge 
questionnaire used in Medication Alliance training (Byrne et al., 2004). Adaptations 
for this study were developed from depression-specific aspects of the training material 
and were designed to test participant knowledge of medication adherence issues and 
ways to facilitate adherence. Four multiple-choice options were given for each 
question and participants were asked to circle the most accurate response. Scores 
could range from 0 to 15. 
Skill 
The Individualised Assessment Exercise was used for the Skill measure. It 
consisted of a case vignette of a patient with a depressive disorder who was variable 
in their adherence to antidepressant medication. Participants were asked to identify as 
many possible variables influencing the patient's adherence, as well as the most likely 
variables influencing adherence, based on the information provided in the vignette. 
Most likely variables were included in the list of possible variables but were viewed as 
variables that implied 'causality' of non-adherence in the sense that they occurred 
immediately prior to a reduction in adherence. A total of 9 possible variables and 5 
most likely variables were imbedded within the vignette. 
Beliefs 
Medication Alliance Beliefs Questionnaire. 
The MABQ (see Study 1) is a 22-item questionnaire which explores clinician 
beliefs about working with individuals who are non-adherent to medication (Byrne et 
al., 2004). Items are rated on a 5-point Likert scale where 1 = "Strongly Disagree" 
through to 5 = ''Strongly Agree'\ Higher responses indicate more positive beliefs with 
the exception of the Pessimism scale where higher responses indicate higher levels of 
pessimism. For data analysis and for consistency in reporting of results, the scores on 
the pessimism subscale were reverse scored. 
The original MABQ was comprised of 5 subscales including Adequacy, 
Legitimacy, Motivation, Work Satisfaction, and Self Esteem (Gorman & Cartwright, 
1991). Byrne et al. (2006) have since used this questionnaire with a sample of 292 
mental health clinicians. Factor analysis yielded 5 subscales that were highly similar 
to the original version of the measure and were used in the present study: Adequacy, 
Empathy, Pessimism, Work Satisfaction, and Self Esteem. Cronbach alpha coefficients 
in the Byrne et al. study (see below for coefficients) show sufficient internal 
consistency for the subscales. 
The Adequacy (a = .83), subscale measures how effectively the clinician 
believes they are able to help individuals with medication adherence issues based on 
their knowledge and skill level (e.g. '7 feel that I can appropriately advise people 
about the use of their medications'"). The Adequacy subscale used in this study is 
identical to \he Adequacy subscale used in Study 1. 
The Empathy subscale (a = .60) measures the clinician's level of empathy for 
individuals with medication adherence issues (e.g. ''I find it hard to imagine what it 
might be like to have medication adherence issues"). 
The Pessimism subscale (a = .65) measures the level of pessimism the 
clinician holds towards working with individuals with medication adherence issues 
(e.g. "/ feel that there is little that I can do to help people who have medication 
adherence issues"). 
The Work Satisfaction subscale (a = .72) measures the level of satisfaction the 
clinician believes they obtain from working with individuals with medication 
adherence issues (e.g. general, it is rewarding to work with people who have 
medication adherence issues''). 
The Self Esteem subscale (a = ,63) measures how much the clinician believes 
they have the personal ability to help individuals with medication adherence issues 
(e.g. "Ai times I feel I am no good at working with people who have medication 
adherence issues"). 
Beliefs about Medicines Questionnaire. 
The General scale of the BMQ (see Study 1) is an 8-item questionnaire 
originally developed by Home et al. (1999) to identify clinicians' beliefs about the 
overuse and harmfulness of medication. The scale items are rated on a 5-point Likert 
scale from 1 = ''Strongly Disagree'' to 5 = ''Strongly Agree". The items provide two 
subscales, Overuse (e.g., "Doctors use too many medications") and Harm ("All 
medications are poisons"). 
Results 
Statistical analyses were performed using the SPSS for Windows (v. 15.0) 
(SPSS Inc., 2006). Of 24 participants 20 completed all pre- and post-training 
measures, 2 completed pre-training measures, and 2 completed post-training measures 
only. Missing data from the 4 participants who did not complete all pre- and post-
training measures was replaced with item means of the total remaining sample of 
participants (Tabachnick Se Fidell, 2001). Matched samples i-tests were performed to 
assess pre- and post-training outcomes. The assumptions of normality for i-tests were 
met for all variables. In an effort to control Type I error for multiple comparisons, a 
Bonferroni adjustment (a = .005) was applied. The significant effects on knowledge 
and beliefs about adequacy and work satisfaction (reported below) are sustained, even 
when the Bonferroni was applied. 
Knowledge 
Statistical analyses for the Knowledge measure are reported in Table 10. The 
post-training mean score for Knowledge was significantly higher than the pre-training 
score. A large effect size for Knowledge was obtained = 1.51; Howell, 1997). 
Skill 
Interrater reliability was conducted for the Skill measure with raters blind to 
pre- and post-training conditions. Raters were two clinical psychologists who were 
trained to rate the skill measure in a 60 minute workshop. Training included reading 
through the skill measure and answers, and practicing scoring of the measure using 
answers generated for training purposes. Scores were based on the content of 
participants' answers, not the total number of answers participants provided (e.g., 
there were 9 specific possible variables and 5 specific most likely variables that, if 
written as an answer, could receive a score). Scoring criteria for content was provided 
to the raters. Pearson's correlation was used to determine interrater reliability for each 
of the variables. The assumptions of normality for conducting the correlation were 
met for all variables. The correlations for the total number of variables identified as 
correct for each respondent were r = .94 (possible variables, pre-training), r = .93 
(possible variables, post-training), r = .86 (most likely variables, pre-training), and r = 
.70 (most likely variables, post-training). 
Statistical data for the Skill measure can be found in Table 11. A small to 
moderate effect size (d = .37) was obtained for the increase in the number of possible 
variables identified from pre- to post-training. However, the increases in both the 
number of possible variables and most likely variables identified from pre- to post-
training did not reach significance. 
Beliefs 
Table 11 shows statistical data for the subscales of the MABQ and the BMQ. 
For the MABQ, a significant increase in beliefs on the Adequacy and Work 
Satisfaction subscales was obtained. A large effect size was obtained for the increase 
in Adequacy beliefs (d = 1.50). No significant differences were found on the 
Pessimism, Self Esteem, and Empathy subscales, though small to moderate effect sizes 
(d= 30, d= .42, J = .56, respectively) were obtained. As the items on the Pessimism 
scale were reverse scored, a higher pessimism score indicates less pessimism. 
Differences over training in the Self Esteem and Empathy subscales would have 
reached significance if the Bonferroni adjustment was not applied. For the BMQ, no 
significant difference in beliefs was obtained on either the Overuse or Harm 
subscales. 
Table 11 
Means (M), Standard Deviations (SD), t-Test Statistics, and Effect Sizes (d)for 
Knowledge, Skill, and Beliefs (MABQ and BMQ) (N = 24) 
Scale/subscale Score Mpre (SD) Mpost (SD) t d P 
range 
Knowledge 0 - 15 6.18 (2.04) 9.27(1.75) -5.96 1.51 .000* 
Skill 
Possible 0 --9 4.73 (2.09) 5.50 (2.10) 1.47 .37 .155 
Most likely 0 --5 .91 (1.02) .95 (0.69) -.21 .04 .833 
MABQ 
Adequacy 6 - 30 18.45 (3.93) 24.36 (2.68) -7.54 1.50 .000* 
Work Satisfaction 3 - 15 10.14(2.35) 11.59 (1.49) -3.35 .62 .003* 
Self Esteem 4 - 20 15.91 (2.95) 17.14 (2.09) -2.68 .42 .014 
Pessimism 3 - 15 13.05 (2.07) 13.68 (1.94) -1.49 .30 .150 
Empathy 3 - 15 11.36(1.52) 12.27 (2.05) -2.48 .56 .021 
BMQ 
Overuse 4 - 20 11.55 (3.07) 12.14 (2.58) -1.50 .19 .147 
Harm 4 - 20 8.14 (2.31) 7.52 (2.33) 1.66 .27 .112 
*p< .005, Bonferroni adjusted,!-tailed 
Discussion 
Study 2 examined the impact of a medication adherence training program on 
primary care allied health clinicians' knowledge, skill, and beliefs to facilitate 
medication adherence among individuals with depressive disorders. The importance 
of delivering such an intervention is highlighted by the lack of such training delivered 
specifically to allied health clinicians working with individuals with depressive 
disorders. Furthermore, this research is unique in that the training program was 
significantly reduced from 3 (see Byrne et al., 2004) to 2 days; a modification that 
makes the training more appealing to an Australian primary care context. 
After attending a 2-day modified version of Medication Alliance (Byrne et al., 
2004), clinicians showed significant improvements in their knowledge and beliefs. 
On average, clinicians correctly answer three more knowledge questions out of a total 
of 15 post-training. Beliefs about adequacy and work satisfaction improved over the 
course of training. However, the 2-day modified version of Medication Alliance 
demonstrated no significant improvements on the skills measure. Prior to training, 
clinicians could identify an average of five out of nine possible variables that may 
influence a patient's use of antidepressant medication. At post-training, clinicians 
only identified an average of one extra possible variable, taking the total possible 
variables identified post-training to an average of six out of nine. The absolute level 
of achievement when identifying the most likely variables that influence adherence is 
one out of five pre-training. This is low and does not increase post-training. 
From these results, the 2-day modified version of Medication Alliance is 
useful for improving allied health clinician knowledge and beliefs. The results do not 
significantly demonstrate it's utility for improving skill. The non-significant result for 
skill could be attributed to a reduction in training time, given that three days of 
training (see Byrne et al., 2004) has previously demonstrated significant skill 
improvements. Byrne et al. found a significant increase in the number of possible 
variables identified from four out of nine pre-training, to five out of nine post-
training. Byrne et al. also found a significant increase in the number of most likely 
variables identified from one out of five pre-training, to two out of five post-training. 
However, the results from the Byrne et al. study show only a small increase in the 
number of variables identified, which is not unlike the modest changes found in the 
current study. Medication Alliance training over 3 days (see Byrne et al.) may allow 
for more skills practice than the modified 2-day version used in this study. However, 
the significant difference in skill obtained utilising the original 3 days of training 
compared with the 2-day version in the current study is only a small effect to justify 
adding an extra day of training. Maintaining the 2-day program would help to retain 
the appeal that such a brief program has in an Australian primary care context. The 
skill based exercises during training focuses on individualised assessment and 
functional analysis. Therefore, devoting more of the training time to practicing these 
specific skills over the two days may help to improve the impact of training on the 
skill measure, whilst maintaining brief 2-day training. Perhaps clinicians could be 
asked to practice the skills covered in between days of training as homework to allow 
for more time with the Medication Alliance training material as opposed to adding 
another day of training. 
Another consideration for the lack of increase in clinician skill is the moderate 
interrater reliability reported for the number of most likely variables identified both 
pre-training (r = .86) and post-training (r = .70). This suggests that there is only 
moderate agreement among raters on the content of the most likely variables 
identified. To address this issue, the scoring criteria of the skill measure should be 
revised to include more clear descriptions of correct answers and perhaps multiple 
examples of how such answers may be written by participants. In addition, the raters 
should be trained for a longer period of time to allow for more examples of scoring to 
be carried out and compared. 
This research demonstrates that allied health clinicians can be trained in the 
areas of knowledge and beliefs necessary to facilitate medication adherence in a short 
amount of time (e.g. 2 days). This is an important finding given that Study 1 showed 
that more positive beliefs are related to higher self-reported use of adherence 
strategies. In addition, previous research has not specifically demonstrated changes in 
allied health clinicians' knowledge and beliefs necessary to facilitate adherence 
(Byrne et al, 2004; Gray et al., 2003). Rather, previous research has focused on 
enhancing the skills, knowledge, and beliefs of mental health nurses who already are 
assumed to have a role in facilitating adherence (Coombs et al., 2003). The 
importance of focusing on allied health clinicians is highlighted by the findings in 
Study 1 that indicate that while most clinicians believe that facilitating adherence is 
an appropriate professional activity in which to engage, up to 30% do not agree or 
were uncertain. In addition, beliefs about facilitating adherence being an appropriate 
professional activity predict self-reported use of specific adherence strategies. 
Furthermore, training allied health clinicians is important in an Australian primary 
care context as a range of allied health clinicians are responsible for providing 
services to primary care patients with depressive disorders under a raft of government 
initiatives (e.g., Better Outcomes in Mental Health Care and Enhanced Primary 
Care). 
Over the course of training, clinicians showed a significant increase in beliefs 
about their adequacy to facilitate adherence {Adequacy) and the satisfaction they 
obtain from working to facilitate adherence {Work Satisfaction). There were also 
indications that empathy they hold for individuals who are non-adherent {Empathy), 
and their ability to help individuals who are non-adherent {Self Esteem) improved. 
Medication Alliance has previously been found to influence only beliefs about 
adequacy and work satisfaction (Byrne et al., 2004). This suggests that the 
modifications made to the program for this study do not compromise the extent to 
which beliefs are addressed in training. 
A large effect size was found for the increase in adequacy beliefs after 
training, suggesting that Medication Alliance training can significantly enhance these 
beliefs over a 2-day training period. This is a significant finding given that the beliefs 
that clinicians hold about their ability to facilitate adherence have been suggested to 
significantly influence the degree to which they work to facilitate adherence among 
their patients (Byrne et al., 2005; Farris & Schopflocher, 1999; Ramstrom et al., 
2006). The importance of the relationship between adequacy beliefs and engagement 
in strategies to facilitate adherence was also demonstrated in Study 1. Specifically 
clinicians who had more positive beliefs about their adequacy to facilitate adherence 
were more likely to report using strategies to facilitate adherence. This is further 
strengthened by the finding, in Study 1, that more positive beliefs about adequacy 
predict higher self-reported use of specific strategies to facilitate adherence. 
Importantly then. Study 2 has shown that Medication Alliance training is able to 
significantly improve adequacy beliefs. A question to be addressed by future research 
is, does this improvement in adequacy lead to improvements in actual practice (e.g., 
observed use of specific adherence strategies)? 
Clinicians' pessimism about working with individuals who are non-adherent 
to antidepressant medication did not significantly change over the course of training. 
This result was likely obtained due to a ceiling effect observed for the measure of 
pessimism. On pre-training measures, clinicians reported very low pessimism (i.e. M 
= 13.05 out of a total of 15). 
Ratings of beliefs about the use of medication suggest that clinicians, on 
average, do not hold strongly negative or positive beliefs about medication being 
harmful or overused. Rather, the data suggests that there is a degree of variation in 
clinicians' general beliefs about medications being harmful or overused. Training 
does not appear to have a significant impact on clinicians' general beliefs about 
medication. This is likely to have not changed as a result of training as the issues 
surrounding the overuse and harm of antidepressant medications were not specifically 
targeted during training. Furthermore, clinicians' beliefs about specific medication, in 
this instance antidepressants, were not assessed. The BMQ assesses clinicians' beliefs 
about medications in general. If the assessment of beliefs was specific to beliefs about 
antidepressants, the data may have more explanatory power. This may be a topic for 
future research. Obtaining information about general beliefs is important in this study 
given the influence that such beliefs can have on clinicians' engagement in 
medication adherence strategies (see the results from Study 1; Byrne et al., 2005; 
Farris & Schopflocher, 1999; Ramstrom et al., 2006). The fact that this study shows 
clinicians' beliefs about medication are not strongly negative, even prior to training, is 
a positive finding given the influence these beliefs can have on the type of treatment 
provided to patients by clinicians (Byrne et al., 2005; Farris & Schopflocher, 1999; 
Ramstrom et al., 2006). 
The clinicians in this study report an average rate of 23% (range 0% - 75%) of 
their patients on antidepressant medication were non-adherent. This rate of non-
adherence is slightly lower than the average rates of non-adherence reported in 
previous research for similar patient groups; 27% (Study 1), 35% (Cramer & 
Rosenheck, 1998), 25% (Aikens et al., 2005), between 28% and 35% (Lin et al., 
1995; Simon et al., 1993), and 60% (Katon et al, 1992). The difference in rates of 
non-adherence may be explained by different measurements of adherence (e.g. self 
report compared with pill counts) and the length of time patients have already been 
taking medication. For example, Aikens et al. report 25% non-adherence over a 2-
week period and Katon et al. reports higher rates of 60% non-adherence over a 6-
month period. 
Only 18% of clinicians reported they had received previous training in 
medication adherence strategies which further reinforces previous findings that health 
clinicians do not appear to receive adequate training in medication adherence 
strategies (Coombs et al., 2003; Byrne et al., 2004, 2005). Furthermore, this lack of 
previous training highlights the importance of providing training, given evidence that 
training can improve clinicians' skills, knowledge, and beliefs necessary to facilitate 
medication adherence (Byrne et al., 2004; Gray et al., 2003). In Study 1, 36% of 
clinicians reported that they had received previous training. The significantly lower 
rate of clinicians from this study who report receiving previous training may be due to 
different training opportunities available across Australia as clinicians from Study 1 
were predominantly from New South Wales while clinicians from Study 1 were from 
Victoria. 
Limitations 
This study has a number of limitations. Firstly, it examines the impact of 
training on a relatively small sample without a control group for comparison. 
Therefore, the results should be interpreted with some degree of caution. The 
inclusion of nurses in the participant sample does not make this sample a pure allied 
health clinician sample. Therefore degree of representation that this sample provides 
for allied health clinicians is limited, reducing the generalisability of the results. 
However, given the diversity of the participant sample, the results suggest that 
Medication Alliance techniques can be delivered to a wide range of mental health 
clinicians, an important step toward improving care for individuals with medication 
adherence issues (Sawyer & Aroni, 2003). A lack of follow-up of participants after 
training does not allow determination of whether the changes demonstrated 
immediately post-training are maintained over time. 
There is a need for a more thorough assessment of clinician skill. For example, 
the study did not include a video or audiotape of actual samples of clinicians' skills in 
either role plays or with actual patients. Finally, the exclusion of the Role scale (see 
Study 1) is a limitation. Study 1 found that clinicians who had previously received 
training had significantly more positive Role beliefs. In addition, clinicians' Role 
beliefs predicted self-reported use of adherence strategies. It is therefore 
recommended that the Role subscale be included in future studies of Medication 
Alliance training. It may be possible that clinicians seeking Medication Alliance 
training may already view facilitating adherence as an appropriate professional role in 
which to engage. In that case, significant changes may not be observed on the Role 
subscale over the course of training. Nevertheless, it is worth investigating this in 
future studies. 
CONCLUSIONS 
Depression is highly prevalent among primary care patients. However, up to 
44% of patients do not adhere to prescribed antidepressant medication (Lin et al., 
1995). Interventions to increase patient adherence often involve highly trained 
clinicians such as physicians, psychiatrists, and clinical psychologists (Katon et al., 
1999, 2001, 2002; Ludman et al., 2000; Mündt et al., 2001; Vergouwen et al, 2005). 
In Australia adherence interventions may be delivered by a range of clinicians such as 
allied health clinicians given the structure and funding of government health 
initiatives (e.g., Better Outcomes for Mental Health Care Program and Enhanced 
Primary Care). This research identified allied health clinicians' views about 
facilitating adherence in primary care, the extent to which they engage in strategies to 
facilitate adherence, and the impact of a Medication Alliance training program on 
knowledge, skills, and beliefs, necessary to facilitate adherence. 
Study 1 identified beliefs held by primary care allied health clinicians about 
working with patients with depressive disorders who are non-adherent to 
antidepressant medication. Overall, clinicians believe that antidepressant medication 
is an effective treatment for depressive disorders and that facilitating adherence is an 
appropriate role in which they can engage. 
However, many clinicians had not received adequate training in medication 
adherence strategies. This supports previous findings that clinicians lack the skills, 
knowledge, and beliefs necessary to facilitate adherence (Byrne et al., 2005; Coombs 
et al., 2003; Gray, Wykes, Parr, Hails, & Goumay, 2001). Clinicians' beliefs about 
medications, their adequacy to facilitate adherence, and their belief that facilitating 
adherence is an appropriate professional activity, are found to have an impact on the 
extent to which they engage in strategies to facilitate adherence. Specifically, 
clinicians who hold more positive beliefs about medication and their adequacy to 
facilitate adherence, are more likely to engage in self-reported strategies to facilitate 
adherence than clinicians with negative beliefs. Study 1 shows that clinicians who 
have received prior training in medication adherence strategies are more likely to hold 
positive beliefs about medication and their adequacy to facilitate adherence, and 
report greater use of strategies to facilitate adherence than clinicians who have not 
received training. This highlights that there is a clear need for training in medication 
adherence strategies among primary allied health clinicians working with individuals 
with depressive disorders who are non-adherent to antidepressant medication. 
In order to address the need for training among primary care allied health 
clinicians, a modified version of Medication Alliance (Byrne et al., 2004) training was 
delivered to 24 primary care allied health clinicians (Study 2). Over the course of 
training, clinicians demonstrated significant increases in knowledge about medication 
adherence issues and ways to facilitate adherence, and beliefs about working with 
individuals who are non-adherent to antidepressant medication. No significant 
increase in skill was demonstrated after training. This may be due to only moderate 
interrater reliability of the measure or the reduction in training time from 3 days 
(Byrne et al., 2004) to 2 days, compromising the amount of time for skill practice. 
Overall, the results suggest the Medication Alliance training can be modified 
for delivery to allied health clinicians working in primary care setting with individual 
with depressive disorders, and still improve knowledge and adequacy beliefs. The 
delivery of such training to a range of health clinicians is an important step toward 
improving care for primary care patients (Sawyer & Aroni, 2003). The next step in 
this research is to examine the impact that training has on clinical practice and 
whether clinicians who receive training do engage in more use of specific medication 
adherence strategies than clinicians who do not receive training. The development and 
ongoing evaluation of training programs such as Medication Alliance are important 
steps in improving primary health care for patients with depressive disorders. 
REFERENCES 
Adams, J., & Scott, J. (2000). Predicting medication adherence in severe mental 
áis^oxáQxs. Acta Psychiatrica Scandinavica, 101(2), 119-124. 
Aikens, J. E., Nease, D. E., Jr., Nau, D. P., Klinkman, M. S., & Schwenk, T. L. 
(2005). Adherence to maintenance-phase antidepressant medication as a 
function of patient beliefs about medication. Annals of Family Medicine, J(l), 
23-30. 
Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior & Human 
Decision Processes, 50(2), 179-211. 
Ajzen, L, & Fishbein, M. (1980). Understanding attitudes and predicting social 
behavior. Englewood Cliffs, NJ.: Prentice Hall. 
Ajzen, I., & Fishbein, M. (2005). The influence of attitudes on behavior. In D. 
Albarracin, B.T. Johnson, & M.P. Zanna (Eds.) The Handbook of Attitudes (pp. 
173-221) Mahwah, New Jersey: Lawrence Erlbaum Associates. 
Albarracin, D., Johnson, B. T., Fishbein, M., & Muellerleile, P. A. (2001). Theories of 
reasoned action and planned behavior as models of condom use: A meta-
analysis. Psychological Bulletin, 127{\), 142-161. 
Al-Windi, A. (2005). Depression in general practice. Nordic Journal of Psychiatry, 
59(4), 272-227. 
American Psychiatric Association. (1987). Diagnostic and statistical manual of 
mental disorders (3'"̂  ed.). Washington, D.C.: American Psychiatric Publishing, 
Inc. 
American Psychiatric Association. (2000a). Diagnostic and statistical manual of 
mental disorders (4^ ed.). Washington, D.C.: American Psychiatric Publishing, 
Inc. 
American Psychiatric Association. (2000b). Practice guideline for the treatment of 
patients with major depressive disorder. American Journal of Psychiatry, 
757(Suppl. 4), 1-45. 
Angst, J. (1992). Epidemiology of depression. Psychopharmacology, 70(5(Suppl.), 71-
74. 
Angst, J. (1997). A regular review of the long-term follow up of depression. British 
MedicalJournal, 315(1116), 1143-1146. 
Aragonés, E., Pinol, J. L., Labad, A., Masdeu, R. M., Pino, M., & Cervera, J. (2004). 
Prevalence and determinants of depressive disorders in primary care practice in 
Spain. InternationalJournal of Psychiatry in Medicine, 34{\\ 21-35. 
Aslani, P., & du Pasquier, S. (2002). Compliance, adherence or concordance? 
Australian Pharmacist, 21(3), 170-174. 
Australian Bureau of Statistics. (2001). National health survey: Mental health, 
Australia. Canberra: Commonwealth of Australia. 
Bandura, A. (1977). Self-efficacy: Toward a unifying theory of behavioral change. 
Psychological Review, 84, 191-215. 
Bandura, A. (1997). Self-efficacy: The exercise of control New York: W. H. 
Freeman. 
Bascue, L. O., & Zlotowski, M. (1980). Psychologists' practices related to medication. 
Journal of Clinical Psychology, 36(3), 821-825. 
Beck, A. T. (1964). Thinking and depression ü: Theory and therapy. Archives of 
General Psychiatry, 10(6), 561-571. 
Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An 
inventory for measuring depression. Archives of General Psychiatry, 4, 561-571. 
Beck, J. S. (1995). Cognitive therapy: Basics and beyond. N.Y., US: Guilford Press. 
Becker, M. H. (1974). The health belief model and personal health behavior. Health 
Education Monographs, 2(4). 
Berardi, D., Leggieri, G., Ceroni, G. B., Rucci, P., Pezzoli, A., Paltrinieri, E., et al. 
(2002). Depression in primary care. A nationwide epidemiological survey. 
Family Practice, 79(4), 397-400. 
Blazer, D. G., Kessler, R. C., McGonagle, K. A., & Swartz, M. S. (1994). The 
prevalence and distribution of major depression in a national community 
sample: The National Comorbidity Survey. American Journal of Psychiatry, 
151(1), 979-986. 
Bollini, P., Tibaldi, G., Testa, C., & Munizza, C. (2004). Understanding treatment 
adherence in affective disorders: A qualitative study. Journal of Psychiatric & 
Mental Health Nursing, 11(6), 668-674. 
Bordin, E. S. (1979). The generalizability of the psychoanalytic concept of the 
working alliance. Psychotherapy: Theory, Research & Practice, 16(2>), 252-260. 
Brannon, L., & Feist, J. (2000). Health psychology: An introduction to behavior and 
health (4* ed.). Belmont, C.A.: Wadsworth/Thomson Learning. 
Brown, C., Battista, D. R., Bruehlman, R., Sereika, S. S., Thase, M. E., & Dunbar-
Jacob, J. (2005). Beliefs about antidepressant medications in primary care 
patients: Relationship to self-reported adherence. Medical Care, 43, 1203-1207. 
Budd, R. J., Hughes, I. C., & Smith, J. A. (1996). Health beliefs and compliance with 
antipsychotic medication. British Journal of Clinical Psychology, 55(3), 393-
Burke, B. L., Arkowitz, H., & Menchola, M. (2003). The efficacy of motivational 
interviewing: A meta-analysis of controlled clinical trials. Journal of Consulting 
& Clinical Psychology, 71(5), 843-861. 
Byrne, M. K., Deane, F. D., & Caputi, P. (2006). [Statistical analyses for the 
Medication Alliance Beliefs Questionnaire]. Unpublished raw data. 
Byrne, M. K., Deane, F. D., & Coombs, T. (2005). Nurse's beliefs and knowledge 
about medications are associated with their difficulties using patient treatment 
adherence strategies. Journal of Mental Health, 14(5), 513-521. 
Byrne, M. K., Deane, F. D., Lambert, G., & Coombs, T. (2003). Medication Alliance 
with people who have psychotic disorders: Training manual. Wollongong, 
NSW: University of Wollongong, Illawarra Institute for Mental Health. 
Byrne, M. K., Deane, F. P., Lambert, G., & Coombs, T. (2004). Enhancing 
medication adherence: clinician outcomes from the Medication Alliance training 
program. Australian & New Zealand Journal of Psychiatry, 58(4), 246-253. 
Byrne, M. K., & Feros, D. L. (2004a). Medication Alliance with people who have 
depressive disorders: Training manual Wollongong, NSW: University of 
Wollongong, Illawarra Institute for Mental Health. 
Byrne, M. K., & Feros, D. L. (2004b). Medication Alliance with people who have 
depressive disorders: Trainee resource books. Wollongong, NSW: University of 
Wollongong, Illawarra Institute for Mental Health. 
Chang, E. C., & D'Zurilla, T. J. (1996). Relations between problem orientation and 
optimism, pessimism, and trait affectivity: A construct validation study. 
Behaviour Research & Therapy, 34(2), 185-194. 
Christensen, O., Bundgaard, S., & Bech, P. (2001). Prevalence of clinical (major) 
depression in general practice using the DSM-IV version of PRIME-MD. 
International Journal of Psychiatry in Clinical Practice, 5(1), 49-54. 
Cochran, S. D., & Gitlin, M. J. (1988). Attitudinal correlates of lithium compliance in 
bipolar affective disorders. Journal of Nervous & Mental Disease, 176{S), 457-
464. 
Coombs, T., Deane, F. P., Lambert, G., & Griffiths, R. (2003). What influences 
patients' medication adherence? Mental health nurse perspectives and a need for 
education and training. International Journal of Mental Health Nursing, 12(2), 
148-152. 
Cramer, J. A., & Rosenheck, R. (1998). Compliance with medication regimens for 
mental and physical disorders. Psychiatric Services, 49{2\ 196-201. 
Delgado, P. L. (2000). Approaches to the enhancement of patient adherence to 
antidepressant medication treatment. Journal of Clinical Psychiatry, 67(Suppl. 
2), 6-9. 
Demyttenaere, K. (1997). Compliance during treatment with antidepressants. Journal 
of Affective Disorders, 43{\), 27-39. 
Demyttenaere, K. (2001). Compliance and acceptance in antidepressant treatment. 
International Journal of Psychiatry in Clinical Practice, 5(Suppl. 1), S29-S35. 
Derogatis, L. R., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974). The Hopkin's 
Symptom Checklist: A measure of primary symptom dimensions. In P. Pichot & 
R Olivier-Martin (Eds.), Psychological measurements in psychopharmacology: 
Problems in pharmacopsychiatry (pp. 267). N.Y.: S Karger. 
DiMatteo M. R. (1991)- The psychology of health, illness, and medical care: An 
i n d i v i d u a l perspective. Belmont, C.A.: Brooks/Cole Publishing Company. 
Dunbar-Jacob, J. (1993). Contributions to patient adherence: Is it time to share the 
blame? Health Psychology, 72(2), 91-92. 
Ellis, P. M., & Smith, D. A. (2002). Treating depression: The beyondblue guidelines 
for treating depression in primary care: "Not so much what you do but that you 
keep doing it". Medical Journal of Australia, 176, S77-83. 
Elsom, S. (2002). The therapeutic optimism scale. Melbourne: Monash University. 
Farris, K. B., & Schopflocher, D. P. (1999). Between intention and behavior: An 
application of community pharmacists' assessment of pharmaceutical care. 
Social Science & Medicine, 49{\), 55-66. 
Fishbein, M. (Ed.). (1967). Readings in attitude theory and measurement. Oxford, 
England: Wiley. 
Frank, E. (1997). Enhancing patient outcomes: Treatment adherence. Journal of 
Clinical Psychiatry, 55(Suppl. 1), 11-14. 
Frank, E., Prien, R. F., Jarrett, R. B., Keller, M. B., Kupfer, D. J., Lavori, P. W., et al. 
(1991). Conceptualization and rationale for consensus definitions of terms in 
major depressive disorder: Remission, recovery, relapse, and recurrence. 
Archives of General Psychiatry, 48(9), 851-855. 
Friedman, M. A., Detweiler-Bedell, J. B., Leventhal, H. E., Home, R., Keitner, G. I., 
& Miller, I. W. (2004). Combined psychotherapy and pharmacotherapy for the 
treatment of major depressive disorder. Clinical Psychology: Science and 
Practice, 77(1), 47-68. 
Goldney, R. D. (2003). Depression and suicidal behavior: The real estate analogy. 
Crisis: The Journal of Crisis Intervention & Suicide Prevention, 24(2), 87-88. 
Goldney, R. D., Fisher, L. J., Wilson, D. H., & Cheok, F. (2000). Major depression 
and its associated morbidity and quality of life in a random, representative 
Australian community sample. Australian & New Zealand Journal of 
Psychiatry, 34{6\ 1022-1029. 
Gorman, D., & Cartwright, A. (1991). Implications of using the composite and short 
versions of the Alcohol and Alcohol Problems Perception Questionnaire 
(AAPPQ). British Journal of Addiction, 86(3), 327-334. 
Gray, R., Wykes, T., Edmonds, M., Leese, M., & Goumay, K. (2004). Effect of a 
medication management training package for nurses on clinical outcomes for 
patients with schizophrenia: Cluster randomised controlled trial. British Journal 
of Psychiatry, 185, 157-162. 
Gray, R., Wykes, T., & Goumay, K. (2003). The effect of medication management 
training on community mental health nurse's clinical skills. International 
Journal of Nursing Studies, 40(2), 163-169. 
Gray, R., Wykes, T., Parr, A., Hails, E., & Goumay, K. (2001). The use of outcome 
measures to evaluate the efficacy and tolerability of antipsychotic medication: A 
comparison of Thom graduate and CPN practice. Journal of Psychiatric & 
Mental Health Nursing, 8(3), 191-196. 
Haddock, G., Devane, S., Bradshaw, T., McGovem, J., Tarrier, N., Kinderman, P., et 
al. (2001). An investigation into the psychometric properties of the Cognitive 
Therapy Scale for Psychosis (CTS-Psy). Behavioural & Cognitive 
Psychotherapy, 29(2), 221-233. 
Haley, W. E., McDaniel, S. H., Bray, J. H., Frank, R. G., Heldring, M., Johnson, S. 
B et al. (1998). Psychological practice in primary care settings: Practical tips 
for clinicians. Professional Psychology: Research and Practice, 29(3), 237-244. 
Hasin, D. S., Goodwin, R. D., Stinson, F. S., & Grant, B. F. (2005). Epidemiology of 
major depressive disorder: Resuhs from the National Epidemiologic Survey on 
Alcoholism and Related Conditions. Archives of General Psychiatry, 62(10), 
1097-1106. 
Hawthorne, G., Cheok, F., Goldney, R., & Fisher, L. (2003). The excess cost of 
depression in South Australia: A population-based study. Australian & New 
Zealand Journal of Psychiatry, 57(3), 362-373. 
Haynes, S. N., Leisen, M. B., & Blaine, D. D. (1997). Design of individualized 
behavioral treatment programs using functional analytic clinical case models. 
Psychological Assessment, 9(4), 334-348. 
Haynes, S. N., & Williams, A. E. (2003). Case formulation and design of behavioral 
treatment programs: Matching treatment mechanisms to causal variables for 
behavior problems. European Journal of Psychological Assessment, 19(3), 164-
174. 
Hickie, I. B., Davenport, T. A., Naismith, S. L., Hadzi-Pavlovic, D., Koschera, A. 
(2001). Treatment of common mental disorders in Australian general practice. 
Medical Journal of Australia, 775(Suppl.), S25-S30. 
Hirschfeld, R. M. (2001). Clinical importance of long-term antidepressant treatment. 
British Journal of Psychiatry, 779(Suppl. 42), S4-S8. 
Hoencamp, E., Haffmans, P. M., Griens, A. M., Huijbrechts, I. P., & Heycop ten 
Ham, B. F. (2001). A 3.5-year naturalistic follow-up study of depressed out-
patients. Journal of Affective Disorders, 66, 261-21 
Home, R. (2003). Treatment perceptions and self-regulation. In L. D. Cameron & H. 
Leventhal (Eds.), The self-regulation of health and illness behavior (pp. 138-
154). London: Routledge. 
Home, R., Cooper, V., Fisher, M., & Buick, D. (2001). Beliefs about HIV and 
HAART and the decision to accept or reject HAART. HIV Medicine, 2(3), 195. 
Home, R., Graupner, L., Frost, S., Weinman, J., Wright, S. M., & Hankins, M. 
(2004). Medicine in a multi-cultural society: The effect of cultural background 
on beliefs about medications. Social Science & Medicine, 59(6), 1307-1313. 
Home, R., & Weinman, J. (1999). Patients' beliefs about prescribed medications and 
their role in adherence to treatment of chronic physical illness. Journal of 
Psychosomatic Research, 47{6), 555-567. 
Home, R., & Weinman, J. (2002). Self-regulation and self-management in asthma: 
Exploring the role of illness perceptions and treatment beliefs in explaining non-
adherence to preventer medication. Psychology & Health, 17{\), 17-32 
Home, R., Weinman, J., & Hankins, M. (1999). The Beliefs about Medicines 
Questionnaire: The development and evaluation of a new method for assessing 
the cognitive representation of medication. Psychology & Health, 14{\), 1-24. 
Horvath, A. O. (2000). The therapeutic relationship: From transference to alliance. 
Journal of Clinical Psychology, 56(2), 163-173. 
Howell, D. C. (1997). Statistical methods for psychology (4̂ ^ ed.). Belmont, C.A.: 
Wadsworth Publishing Co. 
Howgego, I. M., Yellowlees, P., Owen, C., Meldrum, L., & Dark, F. (2003). The 
therapeutic alliance: The key to effective patient outcome? A descriptive review 
of the evidence in community mental health case management. Australian & 
New Zealand Journal of Psychiatry, 37(2), 169-183. 
Hughes, I., Hill, B., & Budd, R. (1997). Compliance with antipsychotic medication: 
From theory to practice. Journal of Mental Health, 6(5), 473-489. 
Janz N K & Becker, M. H. (1984). The health belief model: A decade later. Health 
Education Quarterly, 11(\\ 1-47. 
Janz, N. K., Champion, V. L., & Strecher, V. J. (2002). The health belief model. In K. 
Glanz, B. K. Rimer & F. M. Lewis (Eds.), Health behavior and health 
education: Theory research and practice ed., pp. 45-66). San Francisco, 
C.A.: John Wiley & Sons, Inc. 
Jorm, A. F., Christensen, H., & Griffiths, K. M. (2005). Belief in the harmfulness of 
antidepressants: Results from a national survey of the Australian public. Journal 
of Affective Disorders, 88, 47-53. 
Jorm, A. F., Korten, A. E., Jacomb, P. A., Rodgers, B., & Pollitt, P. (1997). Beliefs 
about the helpfulness of interventions for mental disorders: A comparison of 
general practitioners, psychiatrists and clinical psychologists. Australian & New 
Zealand Journal of Psychiatry, 31, 844-851. 
Katon, W., Russo, J., Von Korff, M., Lin, E., Simon, G., Bush, T., et al. (2002). 
Long-term effects of a collaborative care intervention in persistently depressed 
primary care patients. Journal of General Internal Medicine, 77(10), 741-748. 
Katon, W., Rutter, C., Ludman, E. J., Von Korff, M., Lin, E., Simon, G., et al. (2001). 
A randomized trial of relapse prevention of depression in primary care. Archives 
of General Psychiatry, 58(3), 241-247. 
Katon, W., & Schulberg, H. C. (1992). Epidemiology of depression in primary care. 
General Hospital Psychiatry, 14(4), 237-247. 
Katon, W., Von Korff, M., Lin, E., Bush, T., & Ormel, J. (1992). Adequacy and 
duration of antidepressant treatment in primary care. Medical Care, 30(1), 67-
76. 
Katon, W., Von Korff, M., Lin, E., Simon, G., Walker, E., Unuetzer, J., et al. (1999). 
Stepped collaborative care for primary care patients with persistent symptoms of 
depression: A randomized trial. Archives of General Psychiatry, 56(12), 1109-
1115. 
Katon, W., Von Korff, M., Lin, E., Walker, E., Simon, G. E., Bush, T., et al. (1995). 
Collaborative management to achieve treatment guidelines: Impact on 
depression in primary care. Journal of the American Medical Association, 
275(13), 1026-1031. 
Keller, M. B., & Boland, R. J. (1998). Implications of failing to achieve successful 
long-term maintenance treatment of recurrent unipolar major depression. 
Biological Psychiatry, 44{5), 348-360. 
Keller, M. B., Kocsis, J. H., Thase, M. E., Gelenberg, A. J., Rush, A., Koran, L., et al. 
(1998). Maintenance phase efficacy of sertraline for chronic depression: A 
randomized controlled trial. JAMA: Journal of the American Medical 
Association, 280(19), 1665-1672. 
Keller, M. B., Lavori, P. W., Mueller, T. L, Endicott, J., Coryell, W., Hirschfeld, R. 
M., et al. (1992). Time to recovery, chronicity, and levels of psychopathology in 
major depression: A 5-year prospective follow-up of 431 subjects. Archives of 
General Psychiatry, 49{\0), 809-816. 
Kemp, R., Hayward, P., Applewhaite, G., Everitt, B., & David, A. (1996). 
Compliance therapy in psychotic patients: Randomised controlled trial. British 
Medical Journal, 312(1021), 345-349. 
Kemp, R., Kirov, G., Everitt, B., Hayward, P., & David, A. (1998). Randomised 
controlled trial of compliance therapy: 18-month follow-up. BriHsh Journal of 
Psychiatry, 172,413-411. 
Kessler R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., et al. 
(2003). The epidemiology of major depressive disorder: Results from the 
National Comorbidity Survey Replication (NCS-R). JAMA: Journal of the 
American Medical Association, 289(23), 3095-3105. 
Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., 
et al. (1994). Lifetime and 12-month prevalence of DSM-HI-R psychiatric 
disorders in the United States: Resuhs from the National Comorbidity Study. 
Archives of General Psychiatry, 57(1), 8-19. 
Kocsis, J. H., Friedman, R. A., Markowitz, J. C., Leon, A. C., Miller, N. L., 
Gniwesch, L., et al. (1996). Maintenance therapy for chronic depression: A 
controlled clinical trial of desipramine. Archives of General Psychiatry, 55(9), 
769-774. 
Leventhal, H., Brissette, L, & Leventhal, E. A. (2003). The common-sense model of 
self-regulation of health and illness. In L. D. Cameron & H. Leventhal (Eds.), 
The self-regulation of health and illness behavior (pp. 42-65). London: 
Routledge. 
Leventhal, H., Leventhal, E. A., & Contrada, R. J. (1998). Self-regulation, health and 
behavior: A perceptual-cognitive approach. Psychology and Health, 13{A), 717-
733. 
Lin, E. H., Katon, W. J., Von Korff, M., Russo, J. E., Simon, G. E., Bush, T. M., et al. 
(1998). Relapse of depression in primary care: Rate and clinical predictors. 
Archives of Family Medicine, 7(5), 443-449. 
Lin, E. H., Von Korff, M., Katon, W., Bush, T., Simon, G. E., Walker, E., et al. 
(1995). The role of the primary care physician in patients' adherence to 
antidepressant therapy. Medical Care, 55(1), 67-74. 
Ludman, E., Katon, W., Bush, T., Rutter, C., Lin, E., Simon, G., et al. (2003). 
Behavioural factors associated with symptom outcomes in a primary care-based 
depression prevention intervention trial. Psychological Medicine, 35(6), 1061-
1070. 
Ludman, E., Von Korff, M., Katon, W., Lin, E., Simon, G., Walker, E., et al. (2000). 
The design, implementation, and acceptance of a primary care-based 
intervention to prevent depression relapse. International Journal of Psychiatry 
in Medicine, 50(3), 229-245. 
Maidment, R., Livingston, G., & Katona, C. (2002). "Just keep taking the tablets": 
Adherence to antidepressant treatment in older people in primary C2ire. 
IntemationalJournal of Geriatric Psychiatry, 77(8), 752-757. 
Malcolm, S., Ng, J., Rosen, R., & Stone, V. (2003). An examination of HIV/AIDS 
patients who have excellent adherence to HAART. AIDS Care, 75(2), 251-261. 
Marland, G. R., & Cash, K. (2001). Long-term illness and patterns of medicine 
taking: Are people with schizophrenia a unique group? Journal of Psychiatric <& 
Mental Health Nursing, 8(3), 197-204. 
Martin, D. J., Garske, J. P., & Davis, M. (2000). Relation of the therapeutic alliance 
with outcome and other variables: A meta-analytic review. Journal of 
Consulting & Clinical Psychology, 68(3), 438-450. 
Martin, S. C., Jacobsen, P. B., Lucas, D. J., Branch, K. A., & Perron, J. M. (1999). 
Predicting children's sunscreen use: Application of the theories of reasoned 
action and planned behavior. Preventive Medicine: An International Journal 
Devoted to Practice & Theory, 29(\), 37-44. 
Masand, P. S. (2000). Weight gain associated with psychotropic drugs. Expert 
Opinion on Pharmacotherapy, 1(3), 377-389. 
McDaniel, S. H., Belar, C. D., Schroeder, C., Hargrove, D. S., & Freeman, E. L. 
(2002). A training curriculum for professional psychologists in primary care. 
Professional Psychology: Research & Practice, 33{\\ 65-72. 
McLeod, H. J., Deane, F. P., & Hogbin, B. (2002). Changing staff attitudes and 
empathy for working with people with psychosis. Behavioural & Cognitive 
Psychotherapy, 30(4), 459-470. 
Means-Christensen, A. J., Amau, R. C., Tonidandel, A. M., Bramson, R., & Meagher, 
M. W. (2005). An efficient method of identifying major depression and panic 
disorder in primary care. Journal of Behavioral Medicine, 28(6), 565-572. 
Melfi, C. A., Chawla, A. J., Croghan, T. W., Hanna, M. P., Kennedy, S., & Sredl, K. 
(1998). The effects of adherence to antidepressant treatment guidelines on 
relapse and recurrence of depression. Archives of General Psychiatry, 55(12), 
1128-1132. 
Miklowitz, D. J., George, E. L., Richards, J. A., Simoneau, T. L., & Suddath, R. L. 
(2003). A randomized study of family-focused psychoeducation and 
pharmacotherapy in the outpatient management of bipolar disorder. Archives of 
General Psychiatry, 60(9), 904-912. 
Miller, W. R., & Rollnick, S. (1991). Motivational interviewing: Preparing people to 
change addictive behaviour. New York: Guilford Press. 
Miller, W. R., & Rollnick, S. (2002). Motivational interviewing: Preparing people for 
change (2"̂ ^ ed.). New York: Guilford Press. 
Monash University, & Beyondblue: The national depression initiative. (2004a). 
Mental health aptitudes into practice (MAP): Module 1: Introduction to mental 
health and mental illness: Participant guide. Southern Melbourne, VIC: Monash 
University and Beyondblue: The national depression initiative. 
Monash University, & Beyondblue: The national depression initiative. (2004b). 
Mental health aptitudes into practice (MAP): Module 2: Introduction to 
depression: Participant guide. Southern Melbourne, VIC: Monash University 
and Beyondblue: The national depression initiative. 
Montano, D. E., & Kasprzyk, D. (2002). The theory of reasoned action and the theory 
of planned behavior. In K. Glanz, B. K. Rimer & F. M. Lewis (Eds.), Health 
behavior and health education: Theory research and practice ed., pp. 67-
98). San Francisco, C.A.: John Wiley & Sons, Inc. 
Mündt, J. C., Clarke, G. N., Burroughs, D., Brenneman, D. O., & Griest, J. H. (2001). 
Effectiveness of antidepressant pharmacotherapy: The impact of medication 
compliance and patient education. Depression & Anxiety, 75(1), 1-10. 
Murray, C. J. L., & Lopez, A. D. (Eds.). (1996). The global burden of disease: A 
comprehensive assessment of mortality and disability from diseases, injuries, 
and risk factors in 1990 and projected to 2020. Cambridge, M.A.: Harvard 
University Press. 
Nierenberg, A. A., Gray, S. M., & Grandin, L. D. (2001). Mood disorders and suicide. 
Journal of Clinical Psychiatry, (i2(Suppl. 25), 27-30. 
Pampailona, S., Bollini, P., Tibaldi, G., Kupelnick, B., & Munizza, C. (2004). 
Combined pharmacotherapy and psychological treatment for depression: A 
systematic review. Archives of General Psychiatry, 61{1), 714-719. 
Papakostas, G. I., Petersen, T., Pava, J., Masson, E., Worthington, J. J., Ill, Alpert, J. 
E., et al. (2003). Hopelessness and suicidal ideation in outpatients with 
treatment- resistant depression: Prevalence and impact on treatment outcome. 
J o u r n a l of Nervous & Mental Disease, 191{1), 444-449. 
Piccinelli, M., & Wilkinson, G. (1994). Outcome of depression in psychiatric settings. 
British Journal of Psychiatry, 164, 297-304. 
Priest, R. G., Vize, C., Roberts, A., Roberts, M., & Tylee, A. (1996). Lay people's 
attitudes to treatment of depression: Results of opinion poll for defeat depression 
campaign just before its launch. British Medical Journal, 575(7061), 858-859. 
Ramana, R., Paykel, E. S., Cooper, Z., Hayhurst, H., Saxty, M., & Surtees, P. G. 
(1995). Remission and relapse in major depression: A two-year prospective 
follow-up study. Psychological Medicine, 25(6), 1161-1170. 
Ramstrom, H., Afandi, S., Elofsson, K., & Petersson, S. (2006). Differences in beliefs 
between patients and pharmaceutical specialists regarding medications. Patient 
Education & Counseling, 62(2), 244-249. 
Rosenstock, I. M. (1974). The health belief model: Origins and correlates. Health 
Education Monographs, 2, 336-353. 
Rusch, N., & Corrigan, P. W. (2002). Motivational interviewing to improve insight 
and treatment adherence in schizophrenia. Psychiatric Rehabilitation Journal, 
26{\), 23-32. 
Sawyer, S. M., & Aroni, R. A. (2003). Sticky issue of adherence. Journal of 
Paediatrics & Child Health, 59(1), 2-5. 
Shea, M. T., Elkin, L, Imber, S. D., Sotsky, S. M., Watkins, J. T., Collins, J. R, et al. 
(1992). Course of depressive symptoms over follow-up: Findings from the 
National Institute of Mental Health Treatment of Depression Collaborative 
Research Program. Archives of General Psychiatry, 49(10), 782-787. 
Simon, G. E., Von Korff, M., Wagner, E. H., & Barlow, W. (1993). Patterns of 
antidepressant use in community practice. General Hospital Psychiatry, 15(6), 
399-408. 
Spitzer, R. L., Kroenke, K., Linzer, M., Hahn, S. R., Williams, J. B., deGruy, F. V., 
3rd, et al. (1995). Health-related quality of life in primary care patients with 
mental disorders. Results from the PRIME-MD 1000 study. JAMA: Journal of 
the American Medical Association, 2 19), 1511 -1517. 
SPSS Inc. (2006). Statistical package for the social sciences for Windows (v. 15.0). 
Chicago, IL: SPSS Inc. 
Steiner, M., Bell, B., Browne, G., Roberts, J., Gafni, A., Byrne, C., et al. (1999). 
Prevalence of dysthymic disorder in primary care. Journal of Affective 
Disorders, 54{3), 303-308. 
Stem, S. L., Williams, T., Dixon, S. L., Clement, J. A., Butt, Z. A., Schwartzbaum, J. 
A., et al. (1999). Do health professionals' attitudes interfere with the treatment of 
depression? Depression & Anxiety, 9, 151-155. 
Surguladze, S., Timms, P., & David, A. S. (2002). Teaching psychiatric trainees 
"compliance therapy". Psychiatric Bulletin, 26(1), 12-15. 
Tabachnick, B. G., & Fidell, L. S. (2001). Using multivariate statistics (4^ ed.). 
Boston, Mass.: Allyn and Bacon. 
Thase, M. E., Greenhouse, J. B., Frank, E., Reynolds, C. F., 3rd, Pilkonis, P. A., 
Huriey, K., et al. (1997). Treatment of major depression with psychotherapy or 
psychotherapy-pharmacotherapy combinations. Archives of General Psychiatry, 
54{n), 1009-1015. 
Thomicroft, G., & Sartorius, N. (1993). The course and outcome of depression in 
different cultures: 10-year follow-up of the WHO Collaborative Study on the 
Assessment of Depressive Disorders. Psychological Medicine, 23(4), 1023-
Truax, P. (2002). Major depressive disorder. In M. Hersen & L. K. Porzelius (Eds.), 
Diagnosis, conceptualization, and treatment planning for adults: A step-by-step 
guide (pp. 73-111). Mahwah, N.J.: Lawrence Erlbaum Associates, Publishers. 
Tustin, R. (1993). Functional analyses of challenging behaviours of two people with 
intellectual disability. Behaviour Change, 10{\\ 39-46. 
Unuetzer, J., Katon, W., Sullivan, M., & Miranda, J. (1999). Treating depressed older 
adults in primary care: Narrowing the gap between efficacy and effectiveness. 
Milbank Quarterly, 77(2), 225-256. 
VandenBos, G. R., & Williams, S. (2000). Is psychologists' involvement in the 
prescribing of psychotropic medication really a new activity? Professional 
Psychology: Research & Practice, 57(6), 615-618. 
Vergouwen, A. C., Bakker, A., Burger, H., Verheij, T. J., & Koerselman, F. (2005). A 
cluster randomized trial comparing two interventions to improve treatment of 
major depression in primary care. Psychological Medicine, 55(1), 25-33. 
Walters, G. D. (2001). A meta-analysis of opinion data on the prescription privilege 
debate. Canadian Psychology, 42(2), 119-125. 
Weene, K. A. (2002). The psychologist's role in the collaborative process of 
psychopharmacology. Journal of Clinical Psychology, 58(6), 617-621. 
Weinstein, N. D. (1993). Testing four competing theories of health-protective 
behavior. Health Psychology, 12(4), 324-333. 
Weiss, K. A., Smith, T. E., Hull, J. W., Piper, A., & Huppert, J. D. (2002). Predictors 
of risk of nonadherence in outpatients with schizophrenia and other psychotic 
disorders. Schizophrenia Bulletin, 28(2), 341-349. 
Westerfelt, A. (2004). A qualitative investigation of adherence issues for men who are 
HIV positive. Social Work, 49(2), 231-239. 
Williams, J. B., Gibbon, M., First, M. B., Spitzer, R. L., & et al. (1992). The 
Structured Clinical Interview for DSM-HI-R (SCID): H. Multisite testetest 
reliability. Archives of General Psychiatry, 49(S), 630-636. 
Wittchen, H.-U., & Pittrow, D. (2002). Prevalence, recognition and management of 
depression in primary care in Germany: The Depression 2000 study. Human 
Psychopharmacology: Clinical & Experimental 77(Suppl. 1), SI-SI 1. 
World Health Organisation. (2003). The world health report 2003: Shaping the future. 
Geneva, Switzerland: World Health Organisation. 
World Health Organisation, (n.d.). Depression. Retrieved March 6, 2006, from 
http://www.who.int/mental_health/management/depression/defmition/en/ 
Zygmunt, A., Olfson, M., Boyer, C. A., & Mechanic, D. (2002). Interventions to 
improve medication adherence in schizophrenia. American Journal of 
Psychiatry, 759(10), 1653-1664. 
APPENDIX A 
Allied Health Beliefs Questionnaire 
Section AI 
Please place a cross M in the box next to the answer that is relevant for you. 
1. Gender: Male D Female D 2. Age: 
3. Profession: Psychologist 
Other 
Social worker LI Occupational Therapist 
4. Highest degree: PhD DPsyc Masters Honours 
Bachelor • Other 
5. Years worked in your profession (question 3) since accredited: 
6. Number of hours worked per week in your profession (question 3): 
0 - 1 0 • 10-20 2 0 - 3 0 3 0 - 4 0 40 + 
7. In what State do you practice: 
8. What is the name of your local Division of General Practice: 
If unsure, a map of Australia wide Divisions can be found at www.gp.org.au 
9. Do you work in a clinical capacity with patients with a mental illness (e.g. 
providing case management, assessments, treatment, conducting therapy): 
Yes' No l—J No, go to 12 
10. Is any of your clinical work with patients associated with: 
Better Outcomes for Mental Health Care: 
Enhanced Primary Care program (Medicare): 
Yes 
Yes 
No 
No 
11 What is your predominant theoretical model when conducting therapy with 
patients: 
12. Which best describes the type of agency you work in: 
Community Mental Health Centre Community Health Centre 
Hospital • Private practice Other 
13 How many patients do you currently have on your caseload:. 
Section R 
This section includes questions about your general beliefs about medications. 
There are no right or wrong answers, so please provide your honest opinion. 
Please use the following response scale and place a cross M in the box that best 
represents your belief. 
Strongly Disagree 
Disagree 
1 2 
Uncertain Agree Strongly 
Agree 
3 4 5 
1 Doctors use too many medications 
2 People who take medications should stop 
their treatment for a while every now and 
again 
3 Most medications are addictive 
4 Natural remedies are safer than medications 
5 Medications do more harm than good 
6 All medications are poisons 
7 Doctors place too much trust on medications 
8 If doctors had more time with patients they 
would prescribe fewer medications 
Section C 
This section includes questions about your general beliefs about assisting 
patients to make effective use of their psychotropic medications. There are no 
right or wrong answers, so please provide your honest opinion. Place a cross ISI 
in the box that best represents your belief. 
Strongly 
Disagree 
1 
Disagree Uncertain Agree Strongly Agree 
5 
1 I feel I know enough about the reasons why 
people don't use medications to carry out my 
role when working with people who have 
medication adherence issues 
2 I feel I know how to counsel people who have medication adherence issues over the long 
3 I feel that I can appropriately advise people about rhp of their medications 
4 Yf^Qi^mTTh^ a working knowledge of mrHinfio" iidherence issues 
5 with the way I work with people who have medication 
_adhaenceissues 
I feel I know enough about the factors which 
put people at risk of developing problems 
with the use of their medications to carry out 
my role when working with people who have 
medication adherence issues 
Strongly Disagree Uncertain Agree Strongly 
Disagree Agree 
1 2 3 4 5 
Section D 
This section asks questions specific to your work with individuals who have 
depressive disorders and who have been prescribed antidepressant medication, 
1. What percentage of the patients on your caseload have a depressive 
disorder? 
2. What percentage of your patients with a depressive disorder have been prescribed 
antidepressant medication? 
3. What percentage of you patients with a depressive disorder who have been 
prescribed antidepressant medication do you think are non-adherent or variable in 
their adherence to their medication? 
4. How true is it that patients who are non-adherent or variable in their adherence to 
antidepressant medication occupy more of your time than those who are adherent 
to antidepressant medication? (Please circle a number). 
1 
Not At 
All True 
8 9 10 
Completely 
True 
5. The following questions ask about your beliefs about patients with depressive 
disorders who have been prescribed antidepressant medication. There are no 
right or wrong answers so please provide your honest opinion. Place a cross 0 in 
the box that best represents your belief. 
Strongly 
Disagree 
1 
Disagree Uncertain Agree Strongly 
Agree 
5 
I Antidepressant medication is an effective treatment for depressive disorders 
li " Antidepressant medication helps to reduce the symptoms of depressive 
lii -^¡r;:;;;^dpatients who take nntidfC!Hsant medication will get better 
Iv ^jgi^in^atients adhere to antidepressant medication is an appropriate professional 
-„f^ritv fnr me 
Strongly 
Disagree 
1 
Disagree Uncertain Agree Strongly 
Agree 
5 
It is appropriate for clinicians without 
medical training to assist patients with 
medication adherence 
6. The following questions ask about the extent to which you engage in the 
following activities in your work with patients with depressive disorders who 
have been prescribed antidepressant medication and are variable in their 
adherence to anti-depressant medication. There are no right or wrong answers so 
please provide your honest opinion. Place a cross ISI in the box that is most 
relevant for you. 
Not At 
All 
1 
A Little Sometimes Often 
2 3 4 
Almost 
Always 
5 
I I do not get involved with my patient's 
medication adherence 
li I use specific interventions to enhance 
medication adherence 
lii I consult with a physician about my 
patient's medication adherence 
Iv I discuss medication adherence issues 
with my patients 
V I enquire about medication side effects 
with my patients 
Vi I ask my patients to monitor their 
medication adherence 
Vii I provide patients with information about 
medication 
viii I assess the possible causes of my 
patient's medication non-adherence 
Ix I provide motivational strategies to help 
my patients with adherence to medication 
X I encourage my patients to speak to their 
physician about medication adherence 
Xi I use problem solving strategies to 
overcome medication non-adherence 
7 Have you received training on how to enhance medication adherence? 
Y e s U Nol— 
8 If yes, please estimate the number of hours involved in the training: ... 
9 Please briefly describe what the training involved: 
Thank you for completing this questionnaire. 
APPENDIX B 
Medication Alliance Pre-Training Measures Booklet 
Medication 
Alliance 
With People Who Have Depressive Disorders 
Better Outcomes in Mental Health 
Care Clinicians 
Pre-training 
Measures Booklet 
University of Wollongong 
ILIAWARRA INSTITUTE 
FOR MENTAL HEALTH 
1. Name 2. Date 
3. D.O.B. 4. Gender 
5. Profession 
6. Qualifications 
7. Year of completion of highest 
qualification 
8. Current position title 
9. Number of years worked in 
profession 
10. Have you ever worked in mental 
health services? • yes • no 
11. If yes, for how long? 
12. Have you ever attended training 
related specifically to medication 
adherence issues? 
• yes • no 
13. If yes, please outline what the 
training involved, including an 
estimate of number of training 
hours and specific content areas 
(e.g., as part of a university 
course, as an in-service etc) 
14. Have you ever attended training 
related specifically to mmdfulness 
or meditation? 
• yes • no 
15. If yes, please outline what the 
training involved, including an 
estimate of number of training 
hours and specific content areas 
16. How many patients do you have 
on your caseload? 
17. How many of your patients have a 
major depressive disorder? 
18. How many of those patients with a 
major depressive disorder are 
prescribed antidepressant 
medication? 
19. How many of those patients 
prescribed antidepressant 
medication are non-adherent or 
variable in adherence to 
medication? 
20. Of those patients on your case load • more than twice per week 
who • twice per week 
• have depression • once per week 
AND once per fortnight • 
• have been prescribed • once per month antidepressant medication 
AND • every three months 
• less than quarterly • are variable or non-adherent in 
their medication use 
estimate how often you consult 
with them (tick box) 
21. How true is it that patients who are 
non-adherent occupy more of 
your time than those who are 
adherent to antidepressant 
medication? 
1 2 
not at all true 
9 10 
completely true 
Individualised Assessment Exercise 
Please read the following vignette and answer the question: "What may be influencing 
Angeláis use of medication?" In the first column, please list factors that may possibly be 
influencing Angela; and, in the second column, list those factors that are likely to be 
influencing her ('causal variables'). Recording your answer in dot points is fine. Please 
use the answer sheet provided. 
Angela is a 29-year-old single mother with one child. She studies part-time at the local 
university and has managed to maintain acceptable grades. She has major depressive disorder 
that has been well managed on antidepressant medication, although over the last month she 
has become increasingly variable at taking her medication, intermittently missing doses, and 
consequently is becoming unwell. You are wondering why this is so when she is so attached 
to her child and last time she stopped medication her daughter was placed in care. You 
therefore gathered the following information from her in order to undertake a functional 
analysis. 
Angela had been managing quite well financially on her supporting parent benefit and the 
maintenance paid by the father of her child. However her former partner was sent to jail three 
months ago and the maintenance money he was sending her dried up. As a consequence, she 
started falling behind in some bills about 8 weeks ago and she has discussed with you how 
this worries her. On top of this, her daughter started teething last week and is cranky most of 
the time. Angela has said that she thinks that her daughter is more distressed than normal and 
believes that her local GP did not take her concerns about her daughter's distress seriously 
enough when she took her to see him 10 days ago. In fact, Angela has wondered for some 
time if the GP even cares about her welfare at all. 
Angela appears to have a positive personal life, meeting a new man 6 weeks ago for whom 
she cares a lot. He is a little younger than her and she says they enjoy each other's company 
considerably, though sometimes Angela finds him a little too energetic. With all the increased 
activity with her boyfriend, she would forget her medication routine from time-to-time. Since 
reducing her medication and becoming unwell, Angela has not felt like seeing him as much. 
She is concerned that she may be losing interest in him, though she is not sure. She wonders if 
her reduced interest in sex may be behind her feelings for her boyfriend and believes that the 
medication has reduced her libido. 
Angela has never received much help from her family because they don't agree with her 
diagnosis. He father says that she is just an attention getter and that she puts it on. He says 
that is why she cut herself when she was a teenager. Her father states that if she just stopped 
"boozing" she wouldn't be so down and need the medication. Angela disagrees, stating that 
she has been drinking to help her sleep for years and is drinking no more or less now. 
Nonetheless, Angela has tried to cut down on her alcohol use over the last month and this has 
interfered with her sleep. 
USE ANSWER SHEET ON THE NEXT PAGE 
Answers for the Individualised Assessment Exercise 
1. List all possible factors influencing 
Angela's reduced use of medication 
2. List the most likely (causal) factors 
influencing Angela's reduced use of 
medication 
Medication Alliance Beliefs Questionnaire 
The following questions ask you about your general beliefs regarding assisting people 
to make effective use of their antidepressant medications. Please indicate how 
strongly you agree or disagree with these general statements by ticking the box that 
best represents your judgement. Use the key below to help guide your answers. 
5 = strongly agree 
4 = somewhat agree 
3 = neither agree nor disagree 
2 = somewhat disagree 
1 = strongly disagree 
Strongly 
disagree 
Strongly 
agree 
1 
1 I want to work with people who have medication adherence issues. 
2 I feel that the best that I can personally offer people who have medication adherence issues is 
referral to somebody else 
3 I feel that there is little that I can do to help people who have medication adherence issues 
4 I am interested in the reasons that people have for not using their medications and the responses that 
can be made to them 
5 I feel I know enough about the reasons why people don't use medications to carry out my role 
when working with people who have medication 
adherence issues 
6 In general, I feel that I can understand people who have medication adherence issues 
7 In general, one can get satisfaction from working with people who have medication adherence 
issues 
8 I often feel uncomfortable when working with people who have medication adherence issues 
9 I find it difficult to have empathy for people who have medication adherence issues 
Strongly 
disagree 
Strongly 
agree 
10 I feel that I do not have much to be proud of when 
working with people who have medication 
adherence issues 
11 I feel I know how to counsel people who have 
medication adherence issues over the long term 
12 In general, it is rewarding to work with people 
who have medication adherence issues 
13 I feel that I can appropriately advise people about 
the use of their medications 
14 I feel that I have a working knowledge of 
medication adherence issues 
15 I feel that the people that I work with believe that 
I have the right to ask them questions about their 
use of medications when necessary 
16 I cannot understand what it is like for people who 
have medication non- adherence issues 
17 I feel I have a clear idea of my responsibilities in 
helping people who have medication adherence 
issues 
18 I feel that I have the right to ask a person with 
whom I am working for any information that is 
relevant to their use of medications 
19 All in all I am inclined to feel I am a failure when 
working with people who have medication 
adherence issues 
20 I feel I have the right to ask the people that I work 
with questions about their use of medications as 
necessary 
21 On the whole I am satisfied with the way I work 
with people who have medication adherence 
issues 
22 I feel I know enough about the factors which put 
people at risk of developing problems with the use 
of their medications to carry out my role when 
working with people who have medication 
adherence issues 
23 I find it hard to imagine what it might be like to have medication adherence issues 
Strongly 
disagree 
Strongly 
agree 
24 Pessimism is the most realistic attitude to take 
with people who have medication adherence 
issues 
25 At times I feel I am no good at working with 
people who have medication adherence issues 
26 I sometimes feel that I do not have the skills to 
manage issues related to peoples use of 
medications 
27 It is right to persist in trying to persuade an 
individual to take prescribed medication if they 
initially refuse 
28 It may be appropriate for an individual to use 
illicit drugs if they believe that this will help their 
symptoms 
29 Medication is ineffective in reducing an 
individual's symptoms 
30 It is not appropriate for an individual to use illicit 
drugs even if they believe that this will help their 
symptoms 
31 Sometimes I do not have the confidence to 
manage medication use issues 
32 I accept the medical view that depression is an 
illness 
33 Medication is an essential component of any 
treatment plan 
34 The beneficial effects of medication outweigh the 
side effects 
35 It is important to actively involve people with 
major depressive disorders in making decisions 
about their medications 
36 Taking medication prevents an individual's 
symptoms of their illness returning 
37 Too much discussion about medication can make 
people stop using their medication 
38 
39 
I expect most people with a major depressive 
disorder to be non-adherent with their medication 
I can relate to the experiences of those who have 
medication adherence issues 
Medication Alliance Clinician Knowledge Questionnaire 
Please circle the most correct response to each question, 
1. Resistance to taking medication should be seen as: 
a. denial - a trait characteristic requiring confrontation; 
b. needing to be met with logical argument and correction; 
c. an interpersonal behaviour pattern influenced by the therapists behaviour; 
d. an indication that the consumer is unable to comprehend the value of 
medication; 
e. an indication that you should try to work through the carers. 
2. Sub-optimal use of prescribed medication: 
a. is a 'normal' behaviour; 
b. is almost always due to deficits in insight; 
c. indicates that the consumer does not want to work with you; 
d. is best responded to by the psychiatrist or treating GP; 
e. is never likely to change, no matter what you do. 
3. Motivation: 
a. is usually absent in people with depression; 
b. is something that the case manager can try to influence; 
c. is a personality characteristic; 
d. cannot be changed; 
e. none of the above. 
4. Case formulation involves: 
a. identifying things that happened in the patient's developmental period that 
have contributed to the current problem; 
b. identifying the recent events that triggered the problem; 
c. identifying the thoughts and behaviours that maintain the problem; 
d. identifying 'constitutional' predisposition toward having the problem; 
e. all of the above. 
5. The best way to influence medication is to: 
a. apply cognitive behavioural therapy techniques; 
b. educate the patient about their medications; 
c. enlist the support of family and friends in a collaborative approach; 
d. look for functional relationships that involve the person's use of medication 
and try to influence those relationships; 
e. personally administer the medication. 
6. As a general rule, most therapeutic change occurs: 
a. between sessions as the patient does their homework; 
b. during the session; 
c after therapy has been completed, when the patients use their new skills 
independently; d. when the patient gains insight into the importance of treatment; 
e. when the consulting physician is involved. 
7. An illness timeline is: 
a. a countdown to the next hospitalisation; 
b. a method of individual education about medication use; 
c. a way to explain to carers the costs of not taking medication; 
d. an estimation of the period of health given optimal medication use; e. a strategy for the determination of idiosyncratic predictors of mental health and ill health. 
8. The most important task to undertake early in Medication Alliance Therapy is: 
a. making sure that the person understands the importance of continuing to use 
their medications even when they are well; 
b. establishing engagement with the person specific to their medication issues; 
c. setting homework to help identify why they are not using their medications; 
d. setting an agenda about how you will help the person use their medications; 
e. all of the above. 
9. In a functional analytic approach to behaviour change, the first thing to do is: 
a. clearly define the behaviour; 
b. determine the immediate antecedents; 
c. inquire about early life experiences that might have influenced the behaviour; 
d. investigate the consequences maintaining the behaviour; 
e. ask carers what they think is causing the behaviour. 
10. Homework: 
a. should almost always be included at the end of each session; 
b. should be determined by the clinician according to the therapeutic agenda; 
c. should always involve the patient recording something on paper; 
d. need not be reviewed if the session is 'busy'; 
e. none of the above. 
11. Evaluation of how well your medication-related intervention is going should: 
a. be undertaken in some way every session; 
b. be undertaken intermittendy to see how things are going; 
c. always involve formal measurement; 
d. both b and c are true; 
e. none of the above is true. 
12. When using the illness timeline, autobiographical memory problems mean that: 
a. consumers can never benefit from this process; 
b. only with the aid of carers/family a timeline can be completed; 
c. pictures are a better way of getting the information; 
d. the use of a vertical timeline may be more appropriate; 
e. none of the above. 
13. Problem solving 
a. involves a delineation of difficulties and brainstorming strategies to resolve 
those difficulties; 
b. giving consumers answers to their most pressing problems; 
c. allowing consumers to make mistakes so that they have an opportunity to learn 
and grow and human beings; 
d. is only useful in complex cases; 
e. none of the above. 
14. The stress-vulnerability model suggests that we should: 
a. identify consumers for whom little hope is possible; 
b. focus our energy on reducing both vulnerability and stressors; 
c. use psychosocial models as the primary way to manage relapse; 
d. consider the value of anxiety medication to assist the consumer to reduce 
stress levels; 
e. none of the above. 
15. The goal of cognitive behavioural therapy is to: 
a. establish the consumer's biological vulnerability to mental ill health; 
b. link a situation directly with the emotion that follows it; 
c. identify a consumer's unhelpful thoughts and outline for the consumer 
evidence against their dysfunctional beliefs; 
d. teach consumers to tolerate and live with their irrational thoughts; 
e. teach the consumer how to identify, reality-test and correct unhelpful thoughts 
and beliefs. 
Beliefs about Medication Questionnaire 
Please answer the following questions about your views regarding medications in general. 
These are statements that other people have made and we would like you to indicate the 
extent to which you agree or disagree with them by ticking the appropriate box that best 
matches your opinion. Please use the following key to guide your response: 
Strongly 
disagree 
Disagree Uncertain Agree Strongly 
agree 
1 Doctors use too many 
medications 
2 People who take 
medications should stop 
their treatment for a while 
every now and again 
3 Most medications are 
addictive 
4 Natural remedies are safer 
than medications 
5 Medications do more 
harm than good 
6 All medications are 
poisons 
7 Doctors place too much 
trust on medications 
8 If doctors had more time 
with patients they would 
prescribe fewer 
medications 
